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Introduction 
Microvesicles 
 
Microvesicles (MVs) are small extracellular vesicles physiologically secreted by cells in order to guarantee cell to 
cell communication. These MVs can be secreted by different cells, tissues and body compartments such as 
hematopoietic cells, dendritic cells, T and B lymphocytes, platelets, macrophages, mastocytes, epithelial cells, 
fibroblasts and so on. Microvesicles have also been widely detected in various biological fluids including 
peripheral blood, urine and ascitic fluids; their function and composition depend on the cell from which they 
originate (Graves LE, et al., 2004; Piccin A, et al., 2007; Smalley DM, et al., 2008; Taylor DD, and Gercel-Taylor 
C, 2008). Under stress conditions like hypoxia, radiations or oxidative stress, cells tend to secrete more MVs 
(Ratajczak J, et al., 2006). 
Studies over the past few years have shown that microvesicles can contain bioactive molecules, nucleic acids 
and/or proteins (Cocucci E, et al., 2009), where microvesicles packaged with microRNAs (miRNAs) or mRNAs 
are mainly released from progenitors of differentiated cells and tumor cells (Ratajczak J, et al., 2006). Due to their 
heterogenic membrane, cargo, size, origin and function, there is not a precise categorization of the MVs thus, as 
of today, microvesicles are divided in 3 main groups according to their size (Meckes DG, et al., 2011): 
?? Exosomes (40-100nm) 
?? Shedding microvesicles (100nm –1?m) 
?? Apoptotic bodies (1–5?m) 
Exosomes  
The first evidence of exosomes was in 1981 when Trams and colleagues reported that normal and neoplastic cell 
lines exfoliated shedding vesicles with sizes ranging from 40 to 100 nm and a circular morphology, under electron 
microscopy (Trams EG, et al, 1981). 
 
 
 
Figure 1: Electron microscopy on MVs coming from Caski cell line (HPV16 positive) 
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The endocytic pathway is a convoluted web of interconnected sub-compartments with distinct cell localization, pH, l ipid 
and protein composition, in which cells internalize ligands by endocytosis concomitantly with membrane proteins and 
lipids. Exosomes are generated by inward budding of the lumen of internal vesicular compartments derived from 
endosomes (Thery A, et al., 1999). As vesicles accumulate within these endosome-derived compartments, they are 
referred to as multivesicular bodies (MVBs). The internalized material can be sent for degradation through maturation into 
MVBs and fuse together with lysosomes (Bainton D.F., 1981). Alternatively, cargo can be re-routed for recycling or 
secretion. Recycling processe s are categorized into a quicker and a slower pathway depending on the time that proteins 
and lipids take from internalization to exposure back at the cell surface (or release to the extracellular media in case of 
luminal soluble factors) (Mobius W, et al., 2003). Secretion of exosomes requires maturation of early endosomes into 
MVBs, with concomitant formation of intraluminal vesicles (ILVs), and fusion of MVBs with the cell surface to release 
exosomes. ILVs formation is characterized by inward budding of membranes, a process that starts in early endosomes 
but greatly augments as endosomes mature. At any point material can be further internalized to the trans-Golgi network 
and integrated in canonical secretory pathways (Scott CC, et al., 2014). 
 
 
Figure 2: Exosome biogenesis and secretion (Zhang B. et al., 2014) 
 
The exosomes released in the extracellular environment can be transferred to near or distant cells. The 
mechanism by which this occurs is not entirely clear yet but the hypotheses are: 1) l igand receptor interaction, 2) 
lipid membrane fusion and 3) endocytic entry of the exosomes in the recipient cell. 
Proteomic analysis of the exosomes' cargo showed that these MVs contain different types of proteins and lipids, 
mostly coming from the plasma membrane, the cytosol, the nucleus or the endoplasmic reticulum of the donor 
cell. 
 
Figure 3: Molecular composition of exosomes (Rappa G, et al., 2013) 
 3 
Shedding Microvesicles 
Shedding microvesicles d?????????????????????????????????????????????????????????????????????? 
Similar to the exosomes, these MVs contain RNA and microRNA, have a lipid composition and are secreted 
under physiological and stress conditions. These vesicles can also contain integrins, cytokines, chemokines, 
metalloproteases and high levels of phosphatidylserine (Meckes DG, et al., 2011). 
 
Apoptotic Bodies 
Cells undergoing apoptosis partially transform into phosphatidylserine-containing apoptotic bodies, which are 
rapidly engulfed by phagocytes or neighboring cells to inhibit an inflammatory response or prevent the unwanted 
activation of the coagulation system. These microvesicles are covered by a lipid membrane and characterized by 
a large size ??????????????????????? 
Once released, these vesicles can internalize cellular organelles and DNA fragments like oncogenes. Since their 
isolation is more complicated compared to the isolation of exosomes, little is known about their composition, 
cargo and function; despite knowing that they play an important role in the antigen presentation during 
immunosuppression (Meckes DG, et al., 2011). 
 
Microvesicles and tumor microenv ironment 
Although a microvesicle shedding occurs under physiological conditions, aberrant release of microvesicles can 
arise in disease states. Many studies demonstrated that the tumor microenvironment is rich of microvesicles 
secreted by tumor cells, lymphocytes and monocytes, which are located in the tumor tissues. These MVs 
stimulate the production and secretion of several pro-angiogenic factors by the stromal cells, leading to cell 
proliferation, angiogenesis and cellular invasiveness. 
Other than in vitro evidence of a higher production of microvesicles from the tumor cells, patients affected by 
cancer show a higher number of circulating MVs in the bloodstream and this correlates with a worse prognosis of 
the il lness (Rak J, 2010). Microvesicles in cancer patients were first documented in 1978, when they were 
identified in cultures of spleen nodules and lymph nodes of a male patient with Hodgkin disease (Friend C, et al., 
1978). 
Microvesicles shed from tumor cells facilitate transfer of soluble proteins (Iero M, et al., 2008), nucleic acids (Skog 
J, et al., 2008), functional trans-membrane proteins, tissue factors (Del Conde I, et al., 2005), chemokine 
receptors (Mack M. et al., 2000), and receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) 
and human epidermal growth factor receptor 2 (HER2) (Al-Nedawi K, et al., 2008; Sanderson MP, et al., 2008). 
Different studies showed that the presence of specific proteins in the microvesicles is correlated with tumor 
growth.  
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Table 1 summarizes the most important ones. 
 
Protein type 
Proteins of 
interest 
Functional significance References 
Soluble 
Proteases (MMP2, 
MMP9, uPA) 
ECM degradation upon rupture of released 
microvesicles 
(Angelucci et al., 2000; Ginestra et al., 1998; Baj-Krzyworzeka et 
al., 2006; Sidhu et al., 2004)  
VEGF Promotes angiogenesis 
(Baj-Krzyworzeka et al., 2006; Taraboletti et al., 2006;  
Kim et al., 2002)  
Membrane 
associated 
?1 integrin ECM attachment (Dolo et al., 1998; Muralidharan-Chari et al., 2009) 
Proteases 
(MT1MMP, 
Cathepsin B) 
ECM modification and MMP activation 
(Hakulinen et al., 2008; Giusti et al., 2008; Taraboletti et al., 2006; 
Dolo et al., 1998) 
MHC-class I Not defined. Antigen presentation? 
(Dolo et al., 1998; Muralidharan-Chari et al., 2009; 
Baj-Krzyworzeka et al., 2006)  
EGFR Receptor tyrosine kinase signal transfer (Al-Nedawi et al., 2008) 
VAMP3 v-SNARE (Muralidharan-Chari et al., 2009) 
ARF6 Regulation of microvesicle release (Muralidharan-Chari et al., 2009) 
HER2 Receptor signal transfer (Sanderson et al., 2008) 
TNFL6 (FasL) Immune evasion, promotes T-cell apoptosis (Andreola et al., 2002; Huber et al., 2005; Kim et al., 2005) 
LMP-1 Immune evasion; inhibits leukocyte proliferation (Flanagan et al., 2003) 
CD147/EMMPRIN 
Proangiogenic activity and ECM degradation either 
directly or by activation od cancer stem cells 
(Millimaggi et al., 2007; Baj-Krzyworzeka et al., 2006; 
Sidhu et al., 2004)  
Tissue Factor Thrombus formation, activation of cancer stem cells (Zwicker et al., 2009; Milsom et al., 2007) 
MUC1 
Not defined. Facilitates thrombus formation by 
increasing plasma viscosity? 
(Tesselaar et al., 2007) 
Cytoskeleton 
associated 
Actin Not defined. Cortical microvesicle skeleton? 
(Charras et al., 2005; Paluch et al., 2005; 
Muralidharan-Chari et al., 2009) 
Myosin 
Pinching of vesicle neck during release of 
microvesicles 
(McConnell et al., 2009; Muralidharan-Chari et al., 2009) 
 
Table 1: Tumor-derived microvesicles and their potential role in cancer progression (Muralidharan-Chari V, et al., 2009) 
 
Cancer cells interact with the stroma and actively modify the microenvironment to favor their own progression 
(Fidler IJ, et al., 2008). A recent study showed a mechanism of reciprocal communication between cancer cells 
and microvesicles: MVs released by PC3 cells, an invasive prostate cancer cell line, increased motil ity and 
resistance to apoptosis in fibroblasts in the surrounding microenvironment. In turn, the activated fibroblasts shed 
microvesicles to facil itate the migration and invasion of the prostate cancer cell line (Castellana D, et al., 2009). 
Similarly, Di Vizio and colleagues confirmed the role of prostate-tumor-derived microvesicles in the ‘activation’ of 
stromal cells in the tumor microenvironment (Di Vizio D, et al., 2009). 
Matrix degradation is essential for promoting tumor growth and metastasis (Hotary K, et al., 2006). As indicated 
above, microvesicles that are shed by tumor cells are loaded with proteases and provide additional means of 
matrix degradation, creating a path of least resistance for invading tumor cells. Given the importance of matrix 
degradation in tumor metastases, it is logical to hypothesize that there is a direct correlation between the number 
of invasive microvesicles and tumor progression. 
 
 
 
 
 5 
Microvesicles cargo: viral and mitochondrial components  
Viral components were found in cells in which viral entry should be avoided due to the absence of specific 
receptors on their surface (eg. HPV, HIV). This discovery led to the hypothesis that microvesicles could act as 
mechanism of exit, transfer and entry from a permissive host cell to another. 
The viral contents of exosomes, until now, was investigated for HIV, hepatitis C virus (HCV), HBV, human T-
lymphotropic virus (HTLV), Human Papillomavirus (HPV) and Epstein Bar Virus (EBV). 
In 2000, Mack and colleagues (Mack M, et al., 2000) demonstrated the transfer of the viral HIV CCR5 receptor 
(needed for the virus entry in the host cell), from CCR5 positive cells to CCR5 negative cells through 
microvesicles; this result led to the hypothesis that HIV could use these vehicles to infect cells lacking its receptor 
and help its spread into the host. In 2013, exosomes from HCV-infected cells were shown to be capable of 
transmitting infection to naïve human hepatoma cells and establishing a productive infection. This discovery led to 
the conclusion that viruses could actually use microvesicles to escape the immune system (Ramakrishnaiah V, et 
al., 2013).  
Additionally, microvesicles from lymphoblastoma cells have shown to expose the EBV latent membrane protein 
(LMP-1), another immune-suppressing trans-membrane protein, which inhibited leukocyte proliferation (Flanagan 
J. et al., 2003). Since many viruses, in the absence of a full blown primary infection (CMV, SV40, HHV8 and 
HSV1, HPV, EBV), were found in tumor tissues (Hermann K, and Niedobitek G, 2003; Doorbar J, 2015), as well 
as in sites which are not permissive to viral entry, microvesicles can be considered as a possible mechanism of 
transfer of viral material from a tissue to another.  
Other than viral components, microvesicles can also transfer mitochondria. In particular, a study conducted in 
2013, showed the release of large microvesicles (1 to 8 ?m) from human fetal astrocytes in culture, containing 
mitochondria. They were also able to demonstrate that the mitochondria in the vesicles were active and functional 
(Falchi AM, et al., 2013). 
Oncogenic Viruses 
 
Oncogenic viruses are viruses able to induce tumors in their natural host or in animal models. The first evidence 
that tumors could be caused by viruses was in 1908 when Francis Pyton Rous found that the avian sarcoma 
could be transmitted from host to host without the transfer of a cellular component. This discovery led to the idea 
that particles smaller than cells could be the cause of such pathology (Rous P, 1911). 
After this fundamental discovery many other different viruses linked to cancer development were discovered, like 
the Human Papillomavirus (HPV) and the Epstein Barr Virus (EBV). The possibility that cervical cancer could be a 
sexually transmitted pathology was known since 1800. This is why Haral zur Hausen thought that HPV, known to 
cause genital warts, could be responsible for this neoplasia (zur Hausen H, 1976). He was able to identify high 
risk HPV DNA sequences (HPV16 and HPV18), which were later found to be the most frequent in cervical 
cancers (zur Hausen H, 1983; Boshart M, et al. 1984). Earlier in 1964 the first human oncovirus was described by 
Anthony Epstein, Bert Achong and Yvonne Barr who, thanks to electron microscopy experiments were able to 
identify EBV in African patients affected by Burkitt’ s lymphoma (Epstein MA, et al., 1964). 
The mechanism by which oncoviruses are able to lead to cellular transformation is mediated by the insertion or 
the expression of viral sequences in the host genome, which alter the cellular physiology leading to a higher 
expression of cellular proto-oncogenes or viral proteins production (zur Hausen H, 1999). 
Human oncoviruses are not usually found as viral particles, since they tend to be found in a latent form where the 
viral nucleic acids persist in a plasmidic or episomal form that take advantage of the replicative machinery of the 
host cell in order to divide (zur Hausen H, 2009).  
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Human Papillomavirus  
Classif ication 
Human Papillomaviruses belong to the Papillomaviridae family that contains more than 120 different HPV 
genotypes divided in two groups, called mucosal or epithelial, depending on the site of infection (de Villiers EM, et 
al., 2004). HPV can be transmitted either sexually or by direct contact with an infected sharpened surface that 
determines the formation of epithelial lesions. Some HPVs preferentially infect the epithelial cells of the anogenital 
tract and can be divided in low and high risk depending on their oncogenic potential (de Villiers EM, et al., 2004). 
While the low risk HPVs lead to the formation of genital warts, a benign cellular proliferation, the high risk HPVs 
(eg. HPV16 and HPV18) are responsible of the cervical cancer where HPV16 has been consider the most 
oncogenic HPV subtype, by the Internation Agency for Research on Cancer (IARC). In particular, HPV16 was 
identified in the 60% of the high grade intraepithelial cervical dysplasia, in the 50% of the anogenital cancers and 
somehow in the oral, pharyngeal and lung cancers; HPV18, otherwise, is mostly associated to adenocarcinomas. 
Genome organization 
Human papillomaviruses are small viruses with double stranded DNA (dsDNA) enclosed in an icosahedral capsid 
with 72 capsomers, of 52-55 nm. The viral genome has a length of about 8 Kbps which can be divided in 3 major 
regions called early (E), late (L) and long control region (LCR); the early region encodes for the early oncogenic 
proteins, the late region encodes for the capsid proteins while the LCR is a non coding region containing the 
origin of replication and the transcriptional factor binding region 
The figure schematizes the genomic structure of HPV (Kajitani N, et al., 2012): 
 
 
 
Figure 4: Genomic structure of HPV16 (Kajitani N, et al., 2012) 
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The proteins encoded by the HPVs are 7 and are called E1, E2, E4, E5, E6, E7, L1 and L2. Their functions are 
summarized in table 2: 
Protein                        Function 
   E1                 Viral DNA replication 
   E2         Viral DNA replication; repression of E6/E7 genes 
   E4 Assembly and release of the viral particle 
   E5   Interaction with the Epidermal Growth Factor (EGF) 
   E6         Destruction of p53 tumor suppressor protein 
   E7         Inactivation of pRb tumor suppressor protein 
   L1 Major capsid protein in the viral particle 
   L2 Minor capsid protein in the viral particle 
            Table 2: Protein function of Human Papillomaviruses 
Interacting with p53 protein, E6 impedes it to bind DNA in an effective way, and the p21 protein is therefore not 
available to act as the 'stop signal' for cell division. Thus cells divide uncontrollably, and form tumors. Additionally 
E7 binds to pRb, which cannot longer bind the E2F protein leading to cell proliferation, missing the G1-S cellular 
checkpoint. This causes the division of cells with possible mutation, thus the tumor progression (Giacinti C, 2006). 
HPV life cycle and host transformation 
HPV life cycle is strictly dependent on the differentiation status of its host cell, the keratinocyte, and a number of 
cellular proteins (Stubenrauch F, Lamins LA, 1999). The HPV infection starts in the stem cells of the basal layer, 
when the virus enters the cells through epithelial micro lesions. Once in the cell, the viral DNA goes to the nucleus 
as an extra chromosomal element and its early promoter is activated leading to the production of the E1 and E2 
proteins that start the viral DNA replication producing 50 to 100 episomal copies. The number of DNA copies is 
then kept stable and their replication is linked to the cellular one. When the host cells divide, one differentiates 
while the other one remains stem functioning as a latent viral DNA reservoir. During cell differentiation, instead, 
the late promoter is activated and starts the productive phase of the viral life cycle that implicates the production 
of the late proteins L1 and L2 and the capsid assembly. 
Since the presence of episomal HPV was only found in benign lesions, while integrated sequences of viral DNA 
were found in tumor tissues, this integration step has been considered fundamental for the host cell 
transformation process (Schneider-Maunoury S, et al., 1987). The integration site of HPV in the host genome 
appears random even if it is often found near specific loci l ike c-myc and N-myc, which are known to be fragile 
sites and, in high grade lesions, usually involves the E1 and E2 ORF of the viral DNA. In fact, the E1 and E2 
breakage leads to an uncontrolled synthesis of E6 and E7 proteins with an abnormal cell proliferation as 
consequence. The integration site of HPV-18 in the human genome has been completely mapped in HeLa cells 
by Andrew Adey in 2013 (Adey A, et al., 2013). Adey found out that in chromosome 8q24.21 the integration of the 
HPV-18 genome occurred, which is likely to be the event that initiated tumorigenesis.  
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Epstein Barr Virus (EBV) 
Classif ication 
Herpesviruses are divided into three grou?????-????????????????-herpesviruses and ?-herpesviruses, where the 
Epstein-Barr is classified. They replicate in lymphoblastoid cells in vitro and can cause lytic infections in certain 
targeted cells. Latent viruses were demonstrated in lymphoid tissues. In particular, Epstein Barr virus replicates in 
the epithelial c???????? ???????????????????????-lymphocytes and is transmitted by intimate contact, particularly via 
the exchange of saliva. 
Genome Organization 
                The EBV genome consists of a linear dsDNA of approximately 172 Kbps coated by the capsid proteins and 
surrounded by a tegument layer which is enclosed by an envelope composed of bilayer proteins sandwiched by 
lipids (Odumade OA, et al., 2011). EBV has a series of internal repeat sequences (IRs) that divide the genome 
into short and long, largely unique sequence domains and 0.5 kb terminal direct repeats (TRs), re sponsible of the 
circularization of the viral DNA after infection. The virus has the coding potential for around 85 proteins, not all of 
which have been identified or characterized. During latency only a few viral genes are expressed and the viral 
genome persists as a multi copy circular episome. The episome contains repetitive sequences that serve as 
multiple cooperative binding sites for the viral DNA binding proteins Epstein Barr virus Nuclear Antigen 1 
(EBNA1). 
 
 
Figure 5: Epstein Barr Virus circular dsDNA (SnapGeneViewer Software) 
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EBV Life Cycle and host transformation 
Transcription, genome replication, and capsid assembly occur in the host cell nucleus. Genes are replicated in a 
specific order: 1) immediate-early genes, which encode regulatory proteins; 2) early genes, which encode 
enzymes for viral DNA replication; and 3) late genes, which encode structural proteins. The tegument and 
envelope are acquired as the virion buds out through the nuclear membrane or endoplasmic reticulum. Virions are 
transported to the cell membrane and the host cell dies as mature virions are released. Alternatively, in selected 
cell types, the virus may be maintained in a latent state. The latent viral genome may reactivate at any time even 
though the mechanism of reactivation is not known. 
The cascade of events in the lytic phase of the EBV life cycle is divided into three phases of regulated gene 
expression: immediate–early, early and late. The immediate–early gene products are trans-activator proteins that 
trigger the expression of the early genes, the products of which include enzymes that are required for viral DNA 
replication. In turn, amplification of EBV DNA defines the boundary between early and late gene expression. 
During the late phase of the cycle viral structural proteins are expressed and assembled into virus particles into 
which the DNA is packaged prior to release of infectious virions. 
Studies on EBV have been facilitated since 1984, when Rickinson and colleagues, found that EBV could be 
cultured in vitro by using peripheral blood lymphocytes from healthy EBV sero-positive patients (Rickinson AB, et 
al., 1984); these cells give rise to spontaneous outgrowth of EBV-transformed, immortalized cell l ines which are 
known as lymphoblastic cell lines (LCLs). Every cell now carries multiples copies of circular extra-chromosomal 
viral DNA, which circularizes by homologous recombination of the TRs, and produces a number of latent proteins 
like 6 nuclear antigens (EBNA 1, 2, 3, 3A, 3B, 3C and LP) and 3 latent membrane proteins (LMP 1, 2A and 2B). 
EBV is associated with the development of both lymphoid and epithelial tumors. Its role in oncogenesis has been 
confirmed by its frequent detection in certain tumors like the Burkitt’ s lymphoma (BL), the post-transplant B cell 
lymphomas, the Hodgkin’s disease (HD), the nasopharyngeal carcinoma (NPC) and gastric cancer. In vitro 
experiments also showed the capacity of EBV to transform resting B cells and induce tumors in non-human 
primates (Henle G, et al., 1976; Pope JH, et al., 1968; Miller G, 1974). All tumors are characterized by the 
presence of multiple extrachromosomal copies of the circular viral genome and expression of the EBV-encoded 
latent genes, which appear to contribute to the malignant phenotype (Young LS, et al., 2004). 
Early in the course of primary infection, EBV infects B-lymphocytes, establishing a latent infection, characterized 
by the limited expression of a subset of viral latent genes and small non-coding RNAs, like EBERs 1 and 2. Many 
studies focused on the importance of the latent proteins in oncogenesis, leading to the discovery that EBNA1 is 
required for the maintenance of the episomal EBV genome (Young LS, et al., 2004), while EBNA2 is responsible 
for the activation of LMP1, the major EBV transforming protein. In particular, LMP1 acts up regulating 
antiapoptotic cellular proteins (Henderson S, et al., 1991; Laherty CD, et al., 1992), and stimulating the production 
of cytokines (IL-6, IL-8) (Eliopoulos AG, et al., 1997; Eliopoulos AG, et al., 1999). LMP1 was reported as the 
major oncogenic factor of nasopharyngeal carcinoma (NPC) development and was detected in 80-90% of NPC 
tumors (Pioche-Durieu C, et al., 2005). In addition to the latent proteins, EBERs 1 and 2 are involved in EBV 
mediated pathogenesis, since their presence is correlated with the production of the IL-10 cytokine.  
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The most known latent genes, their proteins and functions are summarized in figure 6: 
                       
          Figure 6: EBV principal v iral latent genes (Leone G, et al., 2009) 
 
Mitochondrial DNA heterogeneity in cancer 
 
Mitochondria are indispensable organelles found in the cellular cytoplasm that orchestrate several homeostatic 
functions of the cell. The primary function of mitochondria is to generate large quantities of energy in the form of 
ATP; they also store calcium for cell signaling activities, generate heat and mediate cell growth and death. Since 
mitochondria are independent organelles evolving from a bacterial progenitor via symbiosis within an essentially 
eukaryotic host cell, they have their own DNA. The mitochondrial genome (mtDNA) is a closed dsDNA molecule 
of about 16.6 Kbs composed of a heavy (H) strand and a light (L) strand. Most of the information is encoded on 
the heavy strand but the 13 protein products encoded by both the heavy (12 polypeptides) and light (1 
polypeptide) strands are constituents of the enzyme complex of the oxidative phosphorylation system (Anderson 
S, et al., 1981; Macreadie IG, et al., 1983; Chomyn A, et al., 1985).  
 
 
Figure 7: Replicating animal mitochondrial DNA (Emily A, et al., 2013) 
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Even if the mitochondrial DNA is extremely small compared to the genomic one and constitutes about the ?1% of 
the total cellular DNA, l ike the genomic DNA, can sustain mutations which can randomly or selectively increase in 
affected tissue s. Several repeats in the mtDNA serve as breakpoints that characterize large-scale deletions, 
where the major one is comprised between the CytB – COI region and flanked by the light and heavy origins of 
replication. Other rare rearrangements are reported, including inversions, simple insertions of small bases of up to 
300 and complex rearrangements with kb inserts. This condition in which mutant and wild type mtDNA coexist is 
called heteroplasmy ad is a known hallmark of mitochondrial disease. Other than changes in the mitochondrial 
genome, changes in its number can occur and this state is linked to certain pathologic conditions and cancers. 
Mitochondrial DNA copy number refers to the number of functional genomes per cell or tissue. Copy number 
changes are important in cancer since they can modulate cancer initiation, cause nuclear genome instabil ity, and 
therapy response. According to a study performed by Brandon and colleagues (Brandon M, et al., 2006), there 
are two distinct types of mtDNA mutations in cancer: 1) pathogenic (possibly carcinogenic), in which the 
probability to compromise the mitochondrial bioenergetics - leading to the increased production of ROS - is high; 
and 2) adaptive mutations, which enable cancer cells to adapt to new microenvironments.  
Since a transfer of nucleic acids between cells through microvesicles was e stablished and demonstrated, it is not 
absurd to hypothesize a possible mechanism of transformation or tumor progression by the transfer of mutated 
mtDNA from already transformed cells to the surrounding wild type ones. 
 
Microvesicles as a tool of nucleic acids transfer 
 
The presence of ssDNA, cDNA (Balaj L, et al., 2011), dsDNA (Thakur BK, et al., 2014), RNA (Skog J, et al., 2008) 
and miRNA (Chen X, et al., 2008; Lawrie CH, et al., 2008; Mitchell PS, et al., 2008), in the microvesicles has been 
demonstrated. In particular, MVs coming from tumor cells in vitro and in vivo showed an amplification of the c-Myc 
oncogene as well as retrotransposon RNA elements together with a higher amount of nucleic acid content 
compared to the MVs coming from healthy donors or normal fibroblasts (Balaj L, et al., 2011).   
In 2010 Pegtel et al., thanks to co-colture experiments, demonstrated the secretion of exosomes containing 
functional viral miRNAs by lymphocytes B infected by EBV (Pegtel DM, et al., 2010). A study conducted in 2012 
characterized the presence of viral DNA in apoptotic bodies coming from HPV positive cells and its transfer to 
primary fibroblasts; interestingly, the recipient fibroblasts showed the typical signs of transformation suggesting 
that the viral content was functional (Gaiffe E, et al., 2012). A part from that, little is known about the viral nucleic 
acids content in the microvesicles.  
Other than viral nucleic acids, exosomes were shown to transfer mitochondrial DNA (Guescini M, et al., 2010), 
leading to the hypothesis that the nucleic acid material transferred from the MVs to the recipient cells, could be 
imported into mitochondria.  
The discoveries that the MVs content could be transferred and change the recipient cells phenotype, led to the 
hypothesis that those MVs could have a role in cancer progression and heterogeneity. In fact, many studies 
described the presence of foreign material (viral nucleic acids or mutated mitochondrial DNA) in cancer tissues 
compared to normal tissues. Microvesicles coming from infected cells or mutated cells could transfer their 
material to recipient cells altering their phenotype and contributing to their transformation.  
Until now, however, there have been no studies that explored the presence of other complex nucleic acid 
structures called R-loops, which are known to form during natural processes such as replication or transcription, 
but are also known to cause genome instabil ity. 
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R-loops 
 
R-loops were first described in 1976 when their formation in vitro was visualized by electron microscopy (Thomas 
M, et al., 1976). In 1994, Drolet and colleagues (Drolet M, et al., 1994), showed the formation of R-loops in live 
bacteria for the first time. Since then, many studies were conducted to understand the biogenesis and role of 
these particular structures. Recent genome-wide approaches permitted the detection of R-loops in many loci 
identifying a high number of putative R-loop-forming sequences (250,000) in 59% of human genes (Wongsurawat 
T, et al., 2012). 
R-loops are structures in which an RNA strand is base paired to the template DNA strand and the non template 
DNA strand remains single stranded. These structures are found both in prokaryotic and eukaryotic organisms 
and are a consequence of transcription processe s. Transcription and high G density zones are necessary for their 
formation (Daniels GA, et al., 1995; Zarrin AA, et al., 2004). Ginno and colleagues recently demonstrated that 
transcription through regions of GC skew leads to the formation of long R-loop structures (Ginno PA, et al., 2012) 
while Helmrich et al., suggested the possibil ity that the R-loops form at common fragile sites (Helmrich A, et al., 
2011). 
 
 
                  Figure 8: Physiological roles of R-loops in cells (Sollier J, and Cimprich KA, 2015) 
 
Mainly, R-loops are known to be necessary during mitochondrial DNA replication (Xu B, and Clayton DA, 1996) 
and immunoglobulin class switch recombination (Yu K, et al., 2003). Other than that, R-loops have were also 
found to participate in epigenetic mechanism like DNA methylation and post-translational histone modification 
(Ginno PA, et al, 2012; Nakama M, et al., 2012; Castellano-Pozo M, et al. 2013; Yang Y, et al. 2014). However 
side effects were discovered; R loops, in fact, can also be dangerous sources of DNA damage, sensitizing DNA to 
damaging agents (Santos-Pereira JM, et al. 2013), inducing transcription associated recombination (Huertas P, 
Aguilera A, 2003), or double-strand breaks (Sordet O, et al. 2009). In particular, a study conducted by Bhatia and 
colleagues (Bhatia V, et al., 2014), correlated an increased formation of R-loops structures in HeLa cells lacking 
the BRCA2 protein, a double-strand break repair factor. They were also able to verify that the formation of R-
loops is also correlated with transcription processe s since, slowing or blocking the transcription fork, leads to the 
formation of DNA:RNA hybrids. 
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Breast cancer 
 
Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 
2012 (second most common cancer overall after lung cancer). This represents about 12% of all new cancer cases 
and 25% of all cancers in women (World Cancer Research Foundation, http://www.wcrf.org/). Breast cancer is a 
hormone related il lness and the factors that modify the risk of this cancer, when diagnosed pre-menopausally or 
post-menopausally, is not the same. It was demonstrated that a third of the breast cancers is related and 
supported by estrogens (Bajetta E, et al., 2000). Mammary cells have specific hormone receptors, particularly for 
progesterone and estrogen and it seems that estrogens are responsible for the induction of cell proliferation 
(Rana A, et al., 2010).  
Breast cancer is an epithelial tumor deriving from an unchecked proliferation of the ductal and lobular cells in the 
mammary gland. It can be separated into different types based on the way the cancer cells look under the 
microscope. Mostly, breast cancer is a carcinoma, a type of cancer that starts in the epithelial cells, or 
adenocarcinoma, which starts in the glandular tissue. Breast cancers can be divided in invasive and not invasive 
cancer. In the first category we can find the ductal carcinoma in situ (DCIS or intraductal carcinoma), in which the 
cells that lined the ducts changed to look like cancer cells but do not spread through the walls of the ducts into the 
surrounding breast tissue. In the invasive breast cancer category we can find two main types of breast cancers, 
the invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). The first one is the most common type 
of breast cancer. It starts in a milk duct of the breast and, after breaking through the wall of the duct, grows into 
the fatty tissue of the breast. Here it can metastasize to other parts of the body through the lymphatic system and 
bloodstream. The second one, instead, starts in the milk-producing glands (lobules) and, l ike the IDC, can 
metastasize. 
 
 
Figure 9: Ductal Carcinoma in Situ (DCIS) (www.cancer.org) 
 
The main difference between each type of breast cancer is the expression of specific genes of the luminal 
epithelial cells, like the estrogen receptor (ER) and the progesterone receptor (PR). 
Normal breast cells and some breast cancer cells contain receptors that attach to estrogen and progesterone. 
These two hormones often fuel the growth of breast cancer cells. Cancer cells may lack, one, or both of these 
receptors. Breast cancers that have estrogen receptors are often referred to as ER-positive (or ER+) cancers, 
while those containing progesterone receptors only are called PR-positive (or PR+) cancers. 
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Considering the hormone receptors and HER-2 status, breast cancers can be classified in 6 main categories: 
1. Hormone receptor-positive: breast cancers which are either estrogen or progesterone receptor positive; 
can be treated with hormone therapy drugs that target the receptors lowering their number or blocking 
them. Women with these cancers tend to have a better prognosis even if it's not rare that the tumor 
comes back many years after treatment. 
2. Hormone receptor-negative: breast cancers without any of the hormone receptors. Treatment with 
hormone therapy drugs is not helpful and it’s for this reason that these types of tumors tend to grow 
more quickly than the hormone receptor-positive cancers.  
3. HER-2 positive: cancers that express or amplify too much HER-2. These cancers can be targeted with 
HER-2 targeting drugs. 
4. HER-2 negative: these cancers don't show an excess of HER2 and thus don't respond to HER2 
targeting drugs. 
5. Triple-negative: cancers that don't have estrogen or progesterone receptors and too much HER2. 
These cancers tend to grow and spread more quickly than all the other types of breast cancer because 
no drugs can be used against them. 
6. Triple-positive: estrogen and progesterone receptor positive cancers; they show a high expression of 
HER-2. These cancers can be treated with hormone receptor drugs and HER2 targeting drugs. 
Thanks to the microarray assay, 4 different types of breast cancer were discovered (Sørlie T, 2004): 
1. Luminal A and Luminal B types: these types of breast cancer are ER+. The gene expression pattern of 
these cancers is similar to normal cells that line the breast ducts and glands. The Luminal A types are 
low grade cancers which tend to grow slowly and show the best prognosis.  
2. The Luminal B cancers grow faster than the A ones, thus the prognosis is worse. 
3. HER2 type: cancers characterized by having extra copies of the HER-2 gene and a high-grade 
appearance under the microscope. They tend to grow quickly and to have a worse prognosis although 
they can be treated with HER-2 targeting drugs and chemotherapy. 
4. Basal type: these types of cancer are usually called triple negative due to the absence of the estrogen 
and progesterone receptors and a low expression of HER2.  
HPV and EBV in breast cancer  
Different studies correlated the insurgence of breast cancer to some viral infections like Simian Virus 40 (SV40), 
Cytomegalovirus (CMV) (Taher C, et al., 2013) and Epstein Barr virus (EBV) (Bonnet M, et al., 1999). 
In 1992 Di Leonardo discovered the presence of HPV16 DNA sequences in the 29.4% of breast cancer tissues 
and some metastatic lymph nodes (Di Leonardo A, et al., 1992). After this discovery many other research groups 
detected HPV DNA sequences in breast cancers worldwide. The prevalence of HPV positive breast cancer is 
reported to vary from the 4% in Mexican to the 86% in American women (Heng B, et al., 2009). In 2012 Simões 
conducted a meta-analysis study estimating a global prevalence of HPV in breast cancers of about the 23% 
(Simões PW, et al., 2012). In 2004 the presence of HPV DNA sequences in breast cancer patients with a cervical 
pathology was discovered (Widschwendter A, et al., 2004), opening the possibility that the HPV viral nucleic acids 
could be transferred from a primary site of infection to a secondary not usual tissue. 
Other than in the breast cancer tissues, HPV sequences were also found in other extragenital lesions like lung 
tumors (Chen YC, et al., 2004), head and neck carcinomas (zur Hausen H, 2009) and glioblastomas (Vidone M, 
et al., 2014). 
The first evidence of the presence of EBV DNA in breast cancer tissues dates back to 1995 when Labracque et 
al., looked for the presence of this virus in almost 100 cases of breast carcinomas and blood samples from the 
same patients; they were able to amplify the viral DNA in the 21% of the breast carcinomas but not in benign 
breast tumors or normal breast tissue s (Labracque LG, et al, 1995). After the publication of these data, many 
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researchers focused on the possible correlation between the presence of the EBV in breast cancer and its 
malignancy. A meta-analysis conducted in 2012 showed that 29.32% of the patients with breast carcinoma were 
positive for EBV with the highest prevalence in Asia (35.25%) and the lowest in the USA (18.27%) (Huo Q, et al., 
2012). Interestingly, the analysis showed a significant increase in breast malignancy risk in patients testing 
positive for the EBV, suggesting that its infection is associated with increased breast carcinoma risk (Huo Q, et 
al., 2012).  
In 2011 Mazouni found EBV DNA sequences in the 33.2% of breast cancer tissues (Mazouni C, et al., 2011). 
Furthermore, EBV positive tumors tended to show a more aggressive phenotype, more frequently ER negative, 
and with a high histological grade. 
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Premise and purpose of the work 
Background 
Microvesicles (MVs) are small extracellular vesicles physiologically secreted by different types of cells (epithelial 
cells, fibroblasts, hematopoietic cells, dendritic cells, T and B lymphocytes, macrophages, and others) in order to 
guarantee cell-to-cell communication. MVs were widely detected in various biological fluids including peripheral 
blood, urine and ascitic fluid; their function and composition depend on the cell from which they originate (Graves 
LE, et al., 2004; Piccin A, et al., 2007; Smalley DM, et al., 2008; Taylor DD, and Gercel-Taylor C, 2008). Under 
stre ss conditions like hypoxia, radiations or oxidative stress, cells tend to secrete more microvesicles and their 
aberrant release can arise in disease states (Ratajczak J, et al., 2006). Due to their heterogenic membrane, 
cargo, size, origin and function, there is not a precise categorization of the MVs thus, as of today, are divided in 3 
main groups according to their size (Meckes DG, et al., 2011): 1) exosomes (40-100nm), 2) apoptotic bodies 
(100nm–1?m), and 3) shedding microvesicles (1–5?m). Studies over the past few years showed that MVs can 
contain bioactive molecules, nucleic acids and/or proteins (Cocucci E, et al., 2009) and that those packaged with 
miRNAs or mRNAs are mainly released from progenitors of differentiated cells and tumor cells (Ratajczak J, et 
al., 2006). Microvesicles shed from tumor cells facilitate transfer of soluble proteins (Iero M, et al., 2008), nucleic 
acids (Skog J, et al., 2008), functional trans-membrane proteins (Del Conde I, et al., 2005), chemokine receptors 
(Mack M. et al., 2000), tissue factors (Del Conde I, et al., 2005), and receptor tyrosine kinases (Al-Nedawi K, et 
al., 2008; Sanderson MP, et al., 2008). Other than in vitro evidence of a higher production of microvesicles by 
tumor cells, patients affected by cancer show a higher number of circulating MVs in the bloodstream. This can 
correlate with a worse prognosis of the illness (Ra k J, 2010). Thus it’s logical to hypothesize that there is a direct 
correlation between the number of invasive microvesicles, their cargo, and tumor progression. 
Viral components were found in cells in which viral entry should be avoided due to the absence of specific 
receptors on their surface (HPV, HIV). This discovery led to hypothesize that MVs could act as mechanism of exit, 
transfer and entry from a permissive host cell to another. 
The viral contents of microvesicles, until now, started to be investigated for HIV, hepatitis C virus (HCV), HBV, 
human T-lymphotropic virus (HTLV), Human Papillomavirus (HPV) and Epstein Bar Virus (EBV). In 2010 the 
secretion of exosomes containing functional viral miRNAs by lymphocytes B infected by EBV was demonstrated 
(Pegtel DM, et al., 2010). A part from another study which characterized the presence of viral DNA in apoptotic 
bodies coming from HPV positive cells and its transfer to primary fibroblasts (Gaiffe E, et al., 2012), l ittle is known 
about the viral nucleic acids content in the microvesicles.  
Oncogenic viruses are able to induce tumor formation in their natural host or in animal models. Human 
papillomaviruses are small epitheliotropic oncoviruses with a dsDNA of about 8 Kbps. There are 120 different 
HPV genotypes; between them, HPV16 and HPV18 were considered the most oncogenic ones by the 
International Agency for Research on Cancer (IARC). In particular, HPV16 was identified in the 60% of the high 
grade intraepithelial cervical dysplasia, in the 50% of the anogenital cancers and somehow in the oral, pharyngeal 
and lung cancers; HPV18, otherwise, is mostly associated to adenocarcinomas. Since the presence of episomal 
HPV DNA was only found in benign lesions, while integrated sequences of viral DNA were found in tumor tissues,  
this integration step has been considered fundamental for the host cell transformation process (Schneider-
Maunoury S, et al., 1987). EBV is an oncovirus characterized by a linear dsDNA of approximately 172 Kbps with 
different internal repeat sequences (IRs) and terminal direct repeats (TRs), re sponsible for the circularization of 
the viral DNA after infection of the host. EBV is associated with the development of both lymphoid and epithelial 
tumors. Its role in oncogenesis was confirmed by its frequent detection in certain tumors like the Burkitt’s 
lymphoma (BL), the post-transplant B cell lymphomas, the Hodgkin’s disease (HD), the nasopharyngeal 
carcinoma (NPC) and the gastric cancer. 
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Although viral DNAs, miRNAs and proteins have been found in different types of microvesicles, the presence of 
viral R-loops structures in the MVs had yet to be demonstrated.  
R-loops are nucleic acids structures in which a RNA strand is base paired to the template DNA strand and the 
non-template DNA strand remains single stranded. R-loops are necessary during the human mitochondrial DNA 
replication (Xu B, and Clayton DA, 1996), immunoglobulin class switch recombination (Yu K, et al., 2003), DNA 
methylation and post-translational histone modification (Ginno PA, et al, 2012; Nakama M, et al., 2012; 
Castellano-Pozo M, et al. 2013; Yang Y, et al. 2014). On the other hand, R loops can also be dangerous sources 
of DNA damage (Santos-Pereira JM, et al. 2013), inducing transcription’s associated recombination (Huertas P, 
Aguilera A, 2003), or double-strand breaks (Sordet O, et al. 2009).  
Other than viral nucleic acids, exosomes were shown to transfer mitochondrial DNA (Guescini M, et al., 2010), 
leading to the hypothesis that the nucleic acid material transferred through MVs to the recipient cells, could be 
imported into mitochondria.  
The mitochondrial genome (mtDNA) is a closed dsDNA molecule of about 16.6 Kbs that encodes for the 
constituents of the enzyme complex of the oxidative phosphorylation system (Anderson S, et al., 1981; Macreadie 
IG, et al., 1983; Chomyn A, et al., 1985). Like genomic DNA, mtDNA can sustain mutations. Other than changes 
in the mtDNA, variations in its molecule number can occur; this phenomenon is l inked to certain pathologic 
conditions and cancers: it’s been demonstrated to modulate cancer initiation, cause nuclear genome instability 
and affect therapy response, even in breast cancer. 
Breast cancer (BC) is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed 
in 2012. It's been demonstrated that a third of breast cancers is related and supported by estrogens (Bajetta E, et 
al., 2000). Mammary cells have specific hormone receptors, particularly for progesterone and estrogen, and looks 
like estrogens are responsible for the induction of cells proliferation (Rana A, et al., 2010). There are many 
different types of BCs; the main difference between each type is the expression of estrogen receptors (ER) and 
progesterone receptors (PR).  
Even if the mammary tissue s are not primary sites of HPV infection and even if this virus is not able to induce 
viremia in the host, Di Leonardo discovered HPV16 DNA sequences in the 29.4% of breast tumors and some 
metastatic lymph nodes (Di Leonardo A, et al., 1992). A meta-analysis study conducted 20 years later (Simões 
PW, et al., 2012) estimated a global prevalence of HPVs in breast cancers of about the 23%. In 2004 the 
presence of HPV DNA sequences in breast cancer patients with a cervical pathology was discovered 
(Widschwendter A, et al., 2004), opening the possibility that the HPV viral nucleic acids could be transported in 
some way from a primary site of infection to a secondary, not permissive, tissue. The first evidence of the 
presence of EBV DNA in breast cancer, instead, dates back to 1995, when Labracque et al., were able to identify 
EBV DNA in a 21% of the samples against a 0% in benign breast tumors or normal breast tissues by PCR assay 
(Labracque LG, et al, 1995). A meta-analysis study conducted in 2012 (Huo Q, et al., 2012), showed that 29.32% 
of the patients with breast carcinoma were positive to the EBV in the tumor tissues. Interestingly, the analysis 
showed a significant increase in breast malignancy risk in patients testing positive for the EBV, suggesting that 
the viral infection was statistically associated with an increased risk of breast carcinoma (Huo Q, et al., 2012). A 
study conducted by Mazouni in 2011 (Mazouni C, et al., 2011) found EBV DNA in the 33.2% of the breast cancer 
tissues analyzed. Again, EBV positive tumors tended to show a more aggressive phenotype, more frequently ER 
negative and with high histological grade.  
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Aim of the study 
 
Since MVs content can be transferred to recipient cells and change their phenotype, the purpose of this study was 
to verify if MVs could have a role in breast cancer heterogeneity and progression by the transfer of viral and 
mitochondrial DNA from donor to recipient cells. In fact, many studies described the presence of foreign material 
(viral nucleic acids or mutated mitochondrial DNA) in cancer tissue s compared to normal tissue s. We therefore 
decided to analyze the presence of viral and mitochondrial nucleic acids in MVs in vitro and ex vivo. By using cell 
lines positive for HPV18/16 (Hela and Caski) and EBV (Namalwa) nucleic acids, we will isolate MVs positive for 
viral DNAs. The quality of the microvesicles will be tested by electron microscopy and NanoSight analysis. These 
MVs will be used for in vitro and in vivo experiments since they will be either exposed on recipient viral-nucleic 
acids-negative cells or injected in breast cancer xenografts. Murine cancer associated fibroblasts (mCAFs) will be 
used for mtDNA transfer analysis: MVs isolated from mCAFs will be exposed on human cell lines in vitro in order 
to evaluate the transfer of the mitochondrial DNA from one cell to another. After the exposure of the recipient cells 
to the MVs, we will analyze the presence of viral and mitochondrial DNA by PCR and qPCR in the recipient cells 
in order to identify the transfer of the nucleic acids in more than one cell l ine model. In vivo experiments will be 
conducted in order to identify the viral DNA in the epithelial neoplastic cells and the surrounding cells, by 
intravenously injecting viral positive microvesicles in xenografts.  
We will also evaluate the presence of both viral and mitochondrial DNA in microvesicles coming from serum of 
patients affected by breast cancer. The specimens collected by two different hospitals, the Sant’Orsola-Malpighi 
Hospital, located in Bologna, Italy, which will supply specimens from newly diagnosed breast cancer patients, and 
the Memorial Sloan Kettering Cancer Center (MSKCC), located in New York, USA, which will give us specimens 
from patients affected by hormonal therapy resistant breast cancer.  
The analysis on the viral DNA and RNA will be conducted for HPV16, HPV18 and EBV, since they’re the most 
frequent viruses found in BCs. The analyses will be conducted by qPCR, PCR and colorimetric in situ 
hybridization (CISH). The chemical and physical structure of the viral nucleic acids in the microvesicles will be 
investigated by nucleases treatments, PCR and qPCR and atomic force microscopy (AFM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
Materials and Methods 
 
Cell lines and culture conditions 
MCF7, ZR75, T47D, BT474 breast cancer cells lines, Caski, HeLa and Namalwa viral DNA positive cell lines (HPV16, 
HPV18 and EBV), were purchased from the American Type Culture Collection (ATCC).  Cells were mycoplasma free. 
Cells were maintained in MEM or RPMI (ATCC and Media Core) supplemented with 5% fetal bovine serum (FBS, Media 
Core), 2 mM glutamine, 100units ml -1 penicillin, and 0.1mg ml -1 streptomycin (Media Core). Cells used for microvesicles 
isolation were supplemented with 5% FBS microvesicles free.  
Cells were either cultured in normoxic (20% O2, 5% CO2) or hypoxic (1% O2) conditions at 37°C from 3 days to a week. 
 
Specimens  
The study population was derived from two different hospitals, the Sant’Orsola-Malpighi Hospital, located in Bologna, Italy, 
and the Memorial Sloan Kettering Cancer Center (MSKCC), located in New York, NY, USA. The Sant’Orsola-Malpighi 
Hospital supplied us with 68 blood samples from newly diagnosed breast cancer patient. All individuals from the Italian 
hospital provided informed consent for blood donation on the approved protocol 145/2015/U/Sper. The MSKCC, instead, 
gave us 65 blood samples from patients affected by hormonal therapy resistant breast cancer. All individuals provided 
informed consent for blood donation on the MSKCC IRB-approved protocol 12-137. 
Xenografts Assays 
All cancer cell lines were engineered to express a GFP positive luciferase expression vector. Prior to in vivo inoculation, 
cancer cells were FACS sorted (for GFP) and injected bilaterally in the mammary fat pads of 5-7 weeks old non-obese 
diabetic/severe combined immunodeficiency mice (NOD/SCID, obtained from NCI Frederick, MD). For each in vivo 
experiment, cancer cells were mixed with an equal volume of MatrigelTM ???? ????????????? ????? ?????? ??????? ??? ??????
Bioluminescence (BLI: Xenogen, Ivis System) was used to monitor both tumour growth (weekly) and metastatic burden (at 
necropsy). Luminal cancer xenografts from the co-injection of human CAFs (HTR bone metastases) and MCF7 cells were 
also generated to determine the effect of the stroma on the generation of de novo resistant endocrine tumors. For 
immunostaining assays: organs were collected and fixed overnight in 4% paraformaldehyde, washed, embedded in 
paraffin and sectioned (Histo-Serve Core). H&E staining was performed by standard methods. For the detection of 
metastases at secondary sites, we performed in vivo BLI as well as immunofluorescence/immunohistochemistry staining 
for GFP and ER. All the surgical procedures and animal care followed the institutional guidelines and an approved 
protocol from our IACUC at MSKCC. 
 
Microvesicles isolation 
Microvesicles isolation from the serum coming from patients affected by hormonal therapy resistant (HTR) luminal breast 
cancer and the cells conditioned media was conducted following the same protocol. Briefly, the conditioned media was 
collected from cells grown in 10 cm dishes and centrifuged for 20’ at 3,000xg at 4°C, as the serum. The supernatant was 
then transferred in ultracentrifuge tubes (Thermo Scientific) and centrifuged for 30’ at 12,500xg at 4°C in a SW32 Ti 
Swinging-Bucket Rotors (Beckman Coulter). After centrifugation, the supernatant was transferred into new ultracentrifuge 
tubes and centrifuged at 100.000xg per 1.30 h at 4°C. The supernatant was discard and the pellet was washed in 1X PBS 
and centrifuged at 100.000xg per 1.30 h at 4°C. The supernatant was discarded and the microvesicles forming the pellet 
were resuspended in 25 µl of 1X PBS. 
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The pellet coming from stromal cells was further resuspended in 25 ml of 1X PBS and loaded on a 5 mls 30% sucrose 
cushion (300g/L sucrose, 24 g/L Tris base, pH 7.4). Samples were centrifuged at 100.000xg per 1.30 h at 37°C. 3.5 mls of 
the cushion, containing microvesicles, were transferred to a new ultracentrifuge tube, fil led with 1X PBS and centrifuged at 
100.000xg per 1.30 h at 37°C. The supernatant was discarded and the pellet resuspended in 25 µl of 1X PBS.  
The microvesicles were treated or not treated, depending on the experiment, with 1 U of Baseline-ZERO?  DNase 
solution (Epicentre®) for 1 hr at 37°C, inactivated by an incubation at 65°C for 10’, in order to get rid of the possible DNA 
stuck to the MVs surface or present in solution.  
 
NanoSight analysis 
Microvesicles isolated by ultracentrifugation were analyzed by using the NS500 nanoparticle characterization system 
(NanoSight, Malvern Instruments) in order to calculate their number/ml and mean size. Briefly, 2 ?l of the microvesicles 
resuspended in 1X PBS were diluted 1:1000 were loaded in the instrument which, thanks to a laser, analyzes the particle 
size, concentration, aggregation and zeta potential. Specifically, the instrument is able to quantify particle whose 
dimension is comprised between 100 and 1000 nm; this is the reason why we conducted electron microscopy analyses on 
the microvesicles as well. Results come out as a diagram file reporting the size distribution of the microvesicles, the mean 
size and their number.  
 
Electron Microscopy (EM)  
Microvesicles were isolated and resuspended in 20 ?l 1X PBS. Cells were washed with serum-free media or appropriate 
buffer. Both MVs and cells were fixed with a modified Karmovsky's fix of 2.5% glutaraldehyde, 4% parafomaldehye and 
0.02% picric acid in 0.1M sodium caocdylate buffer at pH 7.2 (Ito,S 1968). Following a secondary fixation in 1% osmium 
tetroxide, 1.5% potassium ferricyanide (De Bruijn, WC, 1973), samples were dehydrated through a graded ethanol series 
and embedded in an epon analog resin.  
Ultrathin sections were cut using a Fiatome diamond knife (Diatome, USA, Hatfield, PA) on a Leica Ultractu S 
ultramicrotome (Leica, Vienna, Austria). Sections were collected on copper grids and further contrastated with lead citrate 
(Venable JH, and Coggeshall R, 1965.) and viewed on a JEM 1400 electron microscope (JEOL, USA, Inc., Peabody, MA) 
operated at 120 kV.  Images were recorded with a Veleta 2K x2K digital camera (Olympus-SIS, Germany). 
 
DNA Extraction w ith phenol/chloroform from cells  
Cells were scraped off the plate with 2 mls of PBS and centrifuged for 5’ at 1500 rpm. Supernatant was discarded and the 
pellet resuspended in 450 µl of tail buffer (SDS 0.5-1%, Tris-HCl 50 mM pH 8.0, EDTA 0.1 M) and 0,1 mg/ml proteinase K 
20 mg/ml (ThermoFisher Scientific) and incubated O/N at 56°C. After shaking the tubes vigorously, 500 µl of 
phenol/chloroform (ThermoFisher Scientific) were added to each sample and centrifuged at 13,000 rpm for 5’ at room 
temperature. The upper phase, containing the DNA was transferred to a new tube where 500 µl of chloroform were 
added. Samples were centrifuged at 13,000 rpm for 5’ at room temperature; the DNA was washed a second time by 
repeating this step. The upper phase was transferred to a new tube with 450 µl of isopropanol and 50 µl of NaAc 3M. The 
samples were centrifuged at 13,000 rpm for 10’ at 4°C.  The supernatant was discarded and the pellet washed with 750 µl 
70% EtOH and centrifuged at 13,000 rpm for 5’ at 4°C. The DNA pellet was air dried, resuspended in 20 µl of DEPC H2O 
and incubated at 37°C for 30’ to allow DNA resuspension. DNA concentration was measured by loading 1 µl of DNA on a 
Thermo Scientific NanoDrop? 1000 Spectrophotometer and stored at -20°C until use. 
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DNA extraction from microvesicles w ith phenol/chloroform 
Microvesicles coming from ultracentrifugation were resuspended in 25 µl of 1X PBS; 500 µl of tail buffer (SDS 0.5-1%, 
Tris-HCl 50 mM pH 8.0, EDTA 0.1 M) and 2.5 µl proteinase K 20 mg/ml were added. 
After an O/N incubation at 56°C, 500 µl of phenol/chloroform (ThermoFisher Scientific) were added to each sample. 
Samples were centrifuged at 13,000 rpm for 5’ at room temperature. The upper phase, containing the DNA was 
transferred to a new tube where 500 µl of chloroform were added. Tubes were centrifuged at highest speed for 5’ at room 
temperature. The DNA was washed a second time by repeating this step. The upper phase was then transferred to a new 
tube with 450 µl of isopropanol and 50 µl of NaAc 3M. The samples were centrifuged at highest speed for 10’ at 4°C.  The 
supernatant was discarded and the pellet washed with 750 µl of 70% EtOH and centrifuged at highest speed for 15’ at 
4°C. The DNA pellet was dried at room temperature and resuspended in 20 µl of DEPC H2O. The DNA was incubated at 
37°C for 30’ to allow DNA resuspension. DNA concentration was measured by loading 1 µl of DNA on a Thermo Scientific 
NanoDrop? 1000 Spectrophotometer and stored at -20°C until use. 
 
RNA extraction from cells and microvesicles w ith Trizol 
Cells were scraped off the plate with 2 mls of PBS and centrifuged for 5’ at 1500 rpm. The supernatant was discarded and 
the pellet resuspended in 500 µl of Trizol (Invitrogen). Microvesicles were added with 500 µl of Trizol and mixed. The 
samples were centrifuged at 12,000xg for 30 seconds. 200 ?l of chloroform were added, mixed by inversion and 
incubated for 2-3’ at RT. After a centrifugation at 12,000xg for 15’ at 4°C, the upper phase was transferred to a new tube. 
400 ?l  of isopropanol and 3 ?l  of glycogen were added to the sample and incubated O/N at -20°C; the samples were then 
centrifuged at 12,000xg for 10’ at 4°C. The supernatant was discarded and the pellet washed in 750 ?l  of cold 75% EtOH. 
The RNA was pelleted with a centrifugation at 8,000xg for 20’ at 4°C, air dried and resuspended in 10 ?l  of DEPC H2O. 
The RNA concentration was measured with a Thermo Scientific NanoDrop? 1000 Spectrophotometer and treated for 1 
hour at 37°C with 1 U (microvesicles) or 2 U (cells) of Baseline-ZERO™ DNase I (Epicentre®). RNA was stored at -80°C. 
 
 DNA extraction from cells and microvesicles by Trizol  
 
Whenever the samples had to be analyzed by both the DNA and RNA components, DNA extraction by Trizol was 
performed. Cells were scraped off the plate with 2 mls of PBS and centrifuged for 5’ at 1500 rpm. The supernatant was 
discarded and the pellet resuspended in 500 ?l of Trizol (Invitrogen). Microvesicles were added with 500 ?l  of Trizol and 
mixed by pipetting up and down several times. 
The samples were centrifuged at 12,000xg for 30 seconds. 200 ?l  of chloroform were added to the sample, mixed by 
inversion and incubated for 2-3’ at room temperature. After a centrifugation at 12,000xg for 15 minutes at 4°C, the upper 
phase containing the RNA was transferred to a new tube and processed as described before. The remaining phases were 
added with 300 ?l  of 100 EtOH. The samples were mixed by inversion and centrifuged at 2,000xg for 5’ at 4°C. The 
supernatant was discarded and the pellet washed in 1ml of sodium citrate/ethanol solution (0.1M sodium citrate in 10% 
ethanol, pH 8.5). After 30’ of incubation at room temperature, samples were centrifuged at 2,000xg for 5’ at 4°C. This step 
was repeated twice. The supernatant was discarded and 1.5 ml of 75% EtOH were added. After an incubation of 15 
minutes at room temperature, samples were centrifuged at 2,000xg for 5’ at 4°C. The supernatant was removed and 
discarded. The pellet was air dried for 5-10’ at room temperature and resuspended in 20?l of 8mM NaOH. DNA 
concentration was measured by loading 1 µl of DNA on a Thermo Scientific NanoDrop?  1000 Spectrophotometer and 
stored at -20°C until use. 
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Reverse Transcription PCR (RT-PCR)  
 
Reverse transcription PCR was performed on 1 ??????RNA, previously treated with 1 U (microvesicles) or 2 U (cells) of 
Baseline-ZERO™ DNaseI (Epicentre®), by using with the iScript™Select cDNA synthesis Kit (Bio-Rad).  
The reaction mix was prepared as following: 
Reagent Volume (µl) 
iScript select reaction mix (5X) 2 
Random primers 1 
iScript reverse transcriptase 0.5 
H2O Variable 
Sample Variable 
Final Volume = 10 µl 
 
The reverse transcription program was the following: 
Step Temperature (°C) Time (mins) 
Hexamer Incubation 25 5 
Reverse Transcription 42 60 
RT Inactivation 85 5 
 4 Forever 
 
The cDNA was kept at -80°C for further analysis. 
 
Real t ime PCR on DNA and cDNA  
DNA and cDNA were amplified by quantitative PCR (qPCR) using the Applied Biosystem ViiaTM 7 Real-Time PCR System 
in the Power SYBR® Green PCR Master Mix Buffer. Each sample was run in triplicate. DNA amplification was performed 
on 2 ng DNA/reaction; cDNA amplification was performed on 1 microliter of the cDNA/triplicate. The mix of amplification 
was composed as following: 
 
Reagent Volume (µl) 
Power SYBR? Green PCR Master Mix 2X 5 
10 µM primers mix 0.5 
H2O 3.5 
Sample  1 
Final Volume = 10 µl 
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The amplification program was the following: 
 
Step Temperature (°C) Time (secs) Cycles 
UDG Activation 50 120 1 
AmpliTaq?DNA Polymerase Activation 95 120 
40 
Denature 95 15 
Annealing 55-60 15 
Melting 60 60 
 
 
 
All primers used in the Real Time assay are listed in table 1 reported in the last section of material and methods.  
For analysis, ?Ct method was applied and fold change was calculated (2-??Ct). 
In order to verify the specificity of the amplicons, other than the analysis of the Melting Temperature, amplicons were 
visualized on a 2% agarose gel using the ChemiDoc™ XRS+ System (Bio-Rad). 
 
Standard PCR on DNA and cDNA 
The DNA and the RNA were isolated using phenol/chloroform (ThermoFisher Scientific) and Trizol (Invitrogen) 
respectively. Each amplification reaction was performed on a total of 20 ng of DNA or 1 ?????????? in a GeneAmp® PCR 
System 9700, version 2.5, machine. The kit used for the assay is the GoTaq®Flexi DNA Polymerase (Promega).  
 
The amplification mix was the following: 
 
 
Reagent Volume (µl) 
5X Colorless GoTaq® master mix  5 
25 mM MgCl2  2 
10 ?M dNTPs mix  0.5 
10 ?M Primers mix  0.5 
5 U/µl GoTaq®Hot Start Polymerase  0.125 
H2O 15.875 
Sample 1 
Final Volume = 25 µl 
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The amplification program performed for this assay was the following: 
 
Step Temperature (°C) Time (minutes) Cycles 
GoTaq®Hot Start Polymerase Activation 95 2 1 
Denaturation 95 2 
40 
Annealing 60 0.5 
Extension 72 1 
Final Extension 72 5 
 4 Forever  
 
 
All primers used in this assay are listed in table 1 reported in the last section of material and methods.  
Thanks to special sets of primers specific for the viral sequences, we were able to discriminate between the DNA and the 
cDNA in one reaction; the primers used for this purpose are designed to span the intron between two exons so that the 
length of the DNA and cDNA amplicons are different and distinguishable when present in the same sample.  
Amplicons were visualized on a 2% agarose gel using the ChemiDoc™ XRS+ System (Bio-Rad). 
 
Long PCR 
The long PCR was used in order to amplify the whole murine mitochondrial DNA using 3 pairs of overlapping primers. All 
primers used in this assay are listed in table 1 reported in the last section of material and methods. The 5' extremity of the 
primers was modified with an aminoC6 sequence so that the annealing temperature can reach 68°C and lead to a more 
specific amplification. Each amplification reaction was performed on a total of 20 ng of DNA with a GeneAmp®PCR 
System 9700, version 2.5, machine. The PCR was performed using GoTaq®Flexi DNA Polymerase (Promega) kit. The 
PCR master mix was composed as following: 
 
Reagent Volume (µl) 
5X Colorless GoTaq® Master Mix 5 
25mM MgCl2 3 
10 ?M dNTPs mix 1.25 
10 ?M Forward Primer 1.25 
10 ?M Reverse Primer 1.25 
5 U/µl GoTaq®Hot Start Polymerase  0.2 
H2O 12.05 
Sample 1 
Final Volume = 25 µl 
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Samples were amplified using the following program: 
 
Step Temperature (°C) Time (mins) Cycles 
Activation 95 2 1 
Denaturation 95 3 
35 
Annealing 68 20 
Extension 68 10 1 
 
Amplicons were visualized on a 0.8% agarose gel using the ChemiDoc™ XRS+ System (Bio-Rad). 
 
DNA extraction and purif ication from gel 
DNA amplicons resulting from PCR assays were run on gels and the bands of interest extracted using the Nucleospin®Gel 
and PCR clean-up (Macherey-Nagel) following manual’s instruction. Amplicons were eluted in 15 µl of DEPC water and 
quantified at the Bioanalyzer DNA chip using the Agilent 2100 Bioanalyzer Instrument. 
Samples were kept at -20°C and used for Sanger sequencing analysis of standard curve creation for copy number 
calculation. 
 
Copy number quantif ication 
Amplicons extracted by gel were quantified by QC Bioanalyzer DNA chip. The copy number of each amplicon in the 
eluted sample was calculated using the following formula: 
Copy number = (Ng * 6.022x1023) / (Length * 1x109 * 650) 
Where: 
Ng = concentration of the eluted sample,  
6.022X1023 = Avogadro’s number,  
Length = length of amplicon in bps,  
1x109 * 650 = average weight of a base pair in ng.  
 
After copy number quantification, we performed standard curves with serial dilutions of the amplicons of interest by qPCR 
assay in order to verify the quality of the amplification by CTs analysis. Data coming from qPCR assay were interpolated 
in the standard curve. 
 
Microvesicles labeling and transfer to recipient cells 
Microvesicles coming from murine and viral positive cells, isolated by ultracentrifugation, were labeled using the PKH67 
Green Fluorescent Cell Linker Kit for General Cell Membrane Labeling (Sigma-Aldrich®). The microvesicles coming from 
the 1X PBS washing step were firstly resuspended in 500 µl of Diluent C and, subsequently added to a solution containing 
2 µl of PKH67 and 500 µl of Diluent C. The MVs were incubated in the dark for 2-5 minutes at room temperature. The 
reaction was stopped by the addition of a 10% BSA solution. The unbound dye was washed by an ultracentrifugation step 
of 90’ at 100,000xg at 4°C. Microvesicles were resuspended in sterile 1X PBS and exposed on cells or intravenously 
injected.  
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Before being injected in mice, microvesicles were analyzed with Nanosight and a volume containing 108 microvesicles 
was calculated in order to inject the same number of MVs in each mouse, once a week. 
108 microvesicles were also exposed on 105 recipient cells grown in 8 wells cover glass Nunc®Lab-Tek®Chamber Slide 
(Sigma-Aldrich) in 20% O2 and 5% CO2. The chamber slides were incubated under an UV light for 10 minutes. 100 ?l  of 
fibronectin from bovine plasma  (Sigma-Aldrich) were diluted 1:20 in PBS and incubated in the chamber slide for one hour 
and then removed. Cells were plated in the wells with 500 ?l  of growth medium. 
The cells in the wells were stained with the MitoTracker® (ThermoFisher Scientific) in order to visualize the localization of 
the MVs in the recipient cells. Briefly, MitoTracker® was diluted 25nM in growth media and added to the cells for 30 
minutes at 37°C. The solution was removed and replaced by fresh growth media added with 4% formaldehyde for 15 
minutes. After fixation, cells were washed several times and analyzed.  
 
Cryosectioning Tissues 
The tumors collected from the mice were removed and cryosected. After surgery, the tumor was kept in a 4% PFA 
solution O/N at 4°C and then transferred to a 30% sucrose solution until the tissues sinks to the bottom. Tumor was then 
incubated for 1-2 hours in a 1:1 30% sucrose:OCT solution at 4°C and, to a 100% OCT solution for 1 hour, always at 4°C. 
Tissue was finally transferred with the 100% OCT into a mould and put on dry ice for 5 minutes avoiding the formation of 
bubbles. 
 
Chromogenic In Situ hybridization (CISH)  
Chromogenic in Situ Hybridization for HPV and EBV was performed by using the kit ZytoFast®Plus CISH Implementation 
Kit HRP-AEC (ZytoVision) using digoxigenin-labeled probes. Specifically, for the presence of HPV sequences in tissues 
was analyzed by using a probe able to recognize both the HPV16/18 DNA (ZytoFast®HPV type 16/18 Probe Digoxigenin-
labeled) while the EBV was screened by using a probe directed against the EBV EBER-1 and EBER-2 RNAs (ZytoFast® 
EBV-CISH System). As a positive control a probe specific for the ALU sequences (ZytoFast®DNA (+) Control Probe) 
provided by the kit we used. All CISH analyses were performed by following the kit instructions with the only exception 
that the probes were incubated O/N at 37°C. Sections were visualized under a Nikon Eclipse TE300 microscope (Nikon). 
Nuc leases treatment of DNA from microvesicles  
The DNA coming from the microvesicles isolated from cells grown both in hypoxia and normoxia was extracted and 
processed with different nucleases in order to analyze its chemical and physical status. After Nanodrop quantification, the 
samples were divided in 4 aliquots of 200 ng each, which were: 1) not treated, 2) treated with 1 U of Double-strand 
specific DNase (ArcticZymes®), 3) treated with 1 U of ExonucleaseS1 (New England BioLabs®), 4) treated with a 
combination of the two enzymes. After treatment the samples were loaded on a 1% agarose gel and visualized using a 
ChemiDoc™ XRS+ System (Bio-Rad).  
 
Nuc leases treatment of cellular and microvesicles RNA  
The RNA coming from the cells grown in hypoxia or normoxia and from their respective microvesicles was extracted, 
treated with 1 U of Baseline-ZERO?DNase (Epicentre), in order to get rid of contaminating ss- and ds-DNA, and 
processed with different nucleases to analyze its chemical and physical status. After Nanodrop quantification, the samples 
were divided in 5 aliquots of 200 ng of RNA each, which were: 1) not treated, 2) treated with 0.1mg/ml of RNase A 
(Thermo Scientific), 3) treated with 1 ?g of ShortCut®RNase III and 1 U of RNaseH (Thermo Scientific), 4) treated with a 
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combination of the two enzymes and 1 U of ExonucleaseS1 (New England BioLabs®). The enzymes were inactivated by 
heating the samples at 65°C for 10 minutes. Specifically, these RNases digest different types of RNAs like ss- and ds-
RNA (RNa seA) and RNAs present in DNA:RNA hybrid structures (RNaseH) after an incubation of 1 hour at 37°C. 
Enzymes were heat inactivated with an incubation of 10 minutes at 70°C. 
The combination of the two enzymes would free the DNA in the DNA:RNA hybrid structures, which can be further 
digested by the Exonuclease S1. The DNA and the RNA present in the different RNA fractions were used for qPCR 
analyses in order to study the distribution of the housekeeping, mitochondrial and viral genes in the nucleic acids.  
Atomic Force microscopy 
 
The samples treated with different nucleases were analyzed by Atomic Force Microscopy, a technique that allows 
checking the physical status of the DNA based on the brightness and thickness of the nucleic acids. An Asylum Research 
MFP-3D-BIO (Oxford Instruments, Goleta CA) was used to image in tapping mode. An Olympus AC240 (Asylum 
Research, Goleta CA) was used for imaging. The samples were diluted to a suitable concentration in 5 mM MgCl2, 25 mM 
HEPES pH 6.7, plated for 1-10 minutes, and washed with H2O before being dried with N2 gas. 
 
DNA:RNA hybrid Immunoprec ipitation (DRIP)  
A concentration of 5 µg of RNA from cells was incubated overnight with 2 µg of Anti-DNA-RNA Hybrid [S9.6] Antibody 
(KeraFast) under rotation at 4°C in 500 µl of binding buffer (10mM NaPO4 pH 7.0, 140 mM NaCl, 0.05% Triton X-100). 
The following day 25 µl of protein A/G magnetic beads (Pierce™) were washed twice in 500 µl of binding buffer (for 30' 
each wash. The RNA combined with the antibody was added to the beads and incubated for 2 hours at room temperature 
under rotation. 500 µl of the unbound fraction were transferred into a new 1.5 ml tube and collected for further analysis. 
The beads were washed twice in binding buffer for 15' at room temperature under rotation. The DNA/RNA hybrids were 
eluted with 250 µl of elution buffer (50 mM TRIS pH 8.0, 10 mM EDTA, 0.5% SDS) for 15' at room temperature under 
rotation. The elution step was repeated twice. 500 µl of phenol/chloroform (ThermoFisher Scientific) were added to both to 
the unbound and the bound solution and mixed by inverting the tubes. Samples were centrifuged at 13,000 rpm for 5' at 
room temperature and the upper phase collected. 400 µl of isopropanol and 3 µl of glycogen were added and mixed by 
inverting the tubes. Samples were incubate overnight at -20°C. The tubes were incubated for 10 minutes at room 
temperature and centrifuged at 12,000xg for 10' at 4°C. The supernatant was discarded and the pellet was washed in 750 
µl of 75% EtOH. RNA was precipitated by centrifugation at 8,000xg for 10' at 4°C. Supernatant was removed, pellet was 
resuspended in 8 µl of DEPC H2O and incubated for 5' at 65°C. RNA concentration was measured by loading 1 ?l  of DNA 
on a Nanodrop;1000 Spectrophotometer. Samples were stored at -80°C.  
 
Statistical analysis 
Statistical analysis was performed by SPSS (SPSS Incorporation). Continuous variables were analyzed by unequal 
variance t-test, paired t-test (samples, n=2), general linear model (GLM) Anova or GLM for repeated measures (samples, 
n>2). Mann-Whitney, Wilcoxon and Friedman tests were used to analyze ordinal variables. P values were adjusted for 
multiple comparisons according to Bonferroni correction. Association among quantitative variables was quantified by 
????????????????????????????????????????????????????????????????????????????????????? ??????????????????????? ?????????? ????
tests were two-sided. P<0.05 was considered significant. Elda software was used to measure the statistics of limiting 
dilution experiments. 
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Pr imer Tables  
The reference sequences used for primers design are NC_010339 for the murine mitochondrial DNA, NC_012920 for the 
Human mitochondrial DNA, NG_007992 for the human Beta Actin, NG_007073.2 for the human GAPDH, NM_007393.5 
for the murine Beta Actin, NC_001357.1 for Human Papillomavirus type 18, NC_001526 for Human Papillomavirus type 
16, NC_007605 for Epstein Barr Virus. 
 
Table1: Murine Mitochondrial Primers 
Murine Mitochondrial DNA 
Gene Sequence 5'-3' Position Length (bps) Assay Reference 
DLoop 
AGGTTTGGTCCTGGCCTTAT 72 F 
149 
Real Time SnapeGene Viewer Software 
GTGGCTAGGCAAGGTGTCTT 221 R 
12S 
CTAGCCACACCCCCACGGGA 214 F 
114 
CGTATGACCGCGGTGGCTGG 328 R 
16S 
CGGCAAACAAGAACCCCGCC 1912 F 
108 
GTCAGGATACCGCGGCCGTT 2020 R 
ND1  
CAGCCGGCCCATTCGCGTTA 3398 F 
197 
AGCGGAAGCGTGGATAGGATGC 3595 R 
ND2 
TCCTCCTGGCCATCGTACTCAACT 4123 F 
131 
AGAAGTGGAATGGGGCGAGGC 4254 R 
COX1 
CCAGTGCTAGCCGCAGGCAT 5927 F 
127 
TCTGGGTGCCCAAAGAATCAGAACA 6054 R 
COX2  
AGTTGATAACCGAGTCGTTCTGCCA 7425 F 
123 
TCGGCCTGGGATGGCATCAGT 7548 R 
ATP6 
GCTCTCACTCGCCCACTTCCTTCC 8297 F 
529 
GCCGGACTGCTAATGCCATTGGTT 8826 R 
COX3 
ACCTACCAAGGCCACCACACTCC 8804 F 
149 
GCAGCCTCCTAGATCATGTGTTGGT 8953 R 
ND3 
ACCCTACAAGCTCTGCACGCC 9585 F 
385 
GCTCATGGTAGTGAAGTAGAAGGGCA 9970 R 
ND4 L 
TCGCTCCCACCTAATATCCACATTGC 9945 F 
141 
GCAGGCTGCGAAAACCAAGATGG 10086 R 
ND4  
TCGCCTACTCCTCAGTTAGCCACA 11026 F 
115 
TGATGATGTGAGGCCATGTGCGA 11141 R 
ND5 
TCGGAAGCCTCGCCCTCACA 12868 F 
105 
AGTAGGGCTCAGGCGTTGGTGT 12973 R 
ND6  
AATACCCGCAAACAAAGATCACCCAG 13585 F 
99 
TGTTGGGGTTATGTTAGAGGGAGGGA 13684 R 
Cytb 
ACAGCAAACGGAGCCTCAA 14394 F 
134 
TGCTGTGGCTATGACTGCGAACA 14528 R 
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Table 2: Human Mitochondrial Primers 
Human Mitochondrial DNA  
Gene Sequence 5'-3' Position Length (bps) Assay Reference 
DLoop 
TGGCCACAGCACTTAAACACATCTC 321 F 
175 
Real Time 
SnapGene 
Viewer 
Sof tware 
GGGTTGTATTGATGAGATTAGTAGTATGGGAG 496 R 
12S 
CCCGTTCCAGTGAGTTCACCC 706 F 
221 
CTATTGACTTGGGTTAATCGTGTGACC 927 R 
16S 
AACTTTGCAAGGAGAGCCAAAGC 1873 F 
205 
GGGATTTAGAGGGTTCTGTGGGC 2078 R 
ND1 
ACGCCATAAAACTCTTCACCAAAG 3458 F 
103 Real Time/PCR TAGTAGAAGAGCGATGGTGAGAGCTA 3561 R 
ND2 
CTTCTGAGTCCCAGAGGTTACCCA 4805 F 
182 
Real Time 
CCGTCAACTCCACCTAATTTGGTTTG 4987 R 
COX1 
TGCCATAACCCAATACCAAACGC 6425 F 
112 
CTGTTAGTAGTATAGTGATGCCAGCAGCTAGG 6537 R 
COX2 
CTACGGTCAATGCTCTGAAATCTGTG 8161 F 
153 
GCTAAGTTAGCTTTACAGTGGGCTCTAG 8314 R 
ATP6 
GAAAATCTGTTCGCTTCATTCATTGCC 8533 F 
138 
GCTGATTAGTGGTGGGTTGTTACTG 8671 R 
COX3 
CGATACGGGATAATCCTATTTATTACCTCAG 9444 F 
199 
CAGGTGATTGATACTCCTGATGCGA 9643 R 
ND3 
CATTTTGACTACCACAACTCAACGGCTAC 10120 F 
160 
GGGTAAAAGGAGGGCAATTTCTAGATC 10280 R 
ND4L 
GCTACTCTCATAACCCTCAACACCC 10599 F 
130 
AGGCCATATGTGTTGGAGATTGAGA 10729 R 
ND4 
CCAACGCCACTTATCCAGTG 10999 F 
237 
GGGAAGGGAGCCTACTAGGGTGT 11236 R 
ND5 
TTACCACCCTCGTTAACCCTAACAAA 12395 F 
165 Real Time/PCR TGGGTTGTTTGGGTTGTGGCT 12560 R 
ND6 
ACGCCCATAATCATACAAAGCCC 14224 F 
149 
Real Time 
GGATTGGTGCTGTGGGTGAAA 14373 R 
Cyt-b 
CGCCTGCCTGATCCTCCAA 14860 F 
191 
AGGCCTCGCCCGATGTGTAG 15051 R 
Mito 1 
[aminoC6]ACATAGCACATTACAGTCAAATCCCTTCTCGTCCCC 16331 F 
3968 
Long PCR 
Dames S., 
 et al.,  
2015 
[aminoC6]TGAGATTGTTTGGGCTACTGCTCGCAGTGC 3729 R 
Mito 2 
[aminoC6]TACTCAATCCTCTGATCAGGGTGAGCATCAAACTC 3646 F 
5513 
[aminoC6]GCTTGGATTAAGGCGACAGCGATTTCTAGGATAGT 9458 R 
Mito 3  
[aminoC6]TCATTTTTATTGCCACAACTAACCTCCTCGGACTC 8753 F 
9289 
[aminoC6]CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT 16566 R 
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Table 3: Housekeeping Primers 
Housekeeping Genes 
Gene Sequence Position Length (bps) Assay Target Reference 
ACTB 
AGGATCTTCATGAGGTAGTCAGTCAG 1358 F 
98 Real Time DNA Clone Manager 9  (Sci-Ed Software) CCACACTGTGCCCATCTACG 1456 R 
GAPDH 
CTCTGCTCCTCCTGTTCGAC 5030 F 
126 Real Time/PCR DNA 
SnapGene Viewer 
Sof tware CGCCCGCGTCCGGCCTACACA 5156 R 
ACTB 
ACCAACTGGGACGACATGGAG 313 F 
379 Real Time/PCR RNA 
Clone Manager 9  
(Sci-Ed Software) GTGGTGGTGAAGCTGTAGCC 692 R 
 
 
Table 4: HPV 18 Primers 
Human Papillomavirus 18  
Gene Sequence 5'-3' Position Length (bps) Assay Target Reference 
E7 
GAAAGCTCAGCAGACGACCT 818 F 
62 Real Time 
DNA 
Clone Manager 9  
(Sci-Ed Software) 
CACAAAGGACAGGGTGTTCA 880 R 
E6 
TGCACGGAACTGAACACTTCAC 156 F 
345 PCR 
GCCCAGCTATGTTGTGAAATCG 501 R 
GGTGCCAGAAACCGTTGAATC 424 F 
77 Real Time/Nested PCR 
GCCCAGCTATGTTGTGAAATCG 501 R 
ATCCAACACGGCGACCCTAC 121 F 
295/112 PCR DNA/RNA 
ACCGCAGGCACCTCTGTAAG 233 4^16 R 
 
 
Table 5: HPV 16 Primers 
Human Papillomavirus 16 
Gene Sequence 5'-3' Position Length (bps) Assay Target Reference 
E7 
CAACTGATCTCTACTGTTATGAGCAA 617 F 
72 Real Time 
DNA 
Clone 
Manager 9  
CCAGCTGGACCATCTATTTCA 689 R 
(Sci-Ed 
Sof tware) 
E6 
CAACAGTTACTGCGACGTGAG 206 F 
348 PCR 
GCTGGGTTTCTCTACGTGTTC 554 R 
CAACAGTTACTGCGACGTGAG 206 F 
218 Nested PCR AAAGCCACTGTGTCCTGAAGA 424 R 
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Table 6: EBV Primers 
Epstein Barr Virus  
Gene Sequence 5'-3' Position Length (bps) Assay Target Reference 
LMP2 
CTTGGAGACAGGCTTAACCAGACTCA  71232 
264 Real Time DNA 
SnapGene  
Viewer Software 
CCATGGCTGCACCGATGAAAGTTAT  71496 
LMP1 
AAGGCCAAAAGCTGCCAGATGGTGGC  168435 
168/92 PCR DNA/RNA 
ATCTTCGGGTGCTTACTTG  168602 
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Results 
 
Microvesicles analysis  
 
Microvesicles coming from HPV positive cancer cell l ines and murine stromal cell lines undergoing up to 3 rounds of 
hypoxia (1% O2, 4 days, H) and re-oxygenation (20% O2, 3 days, R) were isolated by ultracentrifugation. Specifically, cells 
were firstly cultured in normoxic conditions for 3 days and then in hypoxic conditions for 4 days. These steps were 
repeated three times and after each cycle of HR the microvesicles were collected. A schematic representation of the HR 
treatments is shown in figure 1.  
 
Figure 1: Schematic representation of MVs collection. Cells are grown in normoxic conditions (20%O2) for 3 days and then transferred 
to hypoxic conditions (1% O2) for 4 days. After each HR round MVs were collected by ultracentrifugation, up to 3 rounds 
 
The number and quality of the MVs isolated in normoxic and hypoxic conditions were evaluated by NanoSight and 
electron microscopy. By NanoSight analysis we got information about the size and the number of microvesicles per ml. In 
figure 2 we report a Nanosight diagram of microvesicles coming from cells cultured in normoxic and hypoxic conditions; in 
hypoxia, cells released larger MVs whereas the number is almost doubled, compared to cells from normoxic culture 
conditions.  
 
Normoxia:                       
 
                 
A 
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 Hypoxia:                 
 
        
Figure 2: Nanosight diagram of MVs collected from cells cultured in normoxic or hypoxic conditions. (A) MVs coming from 
normoxic conditions show a lower number and a mean distribution size almost identical compared to (B) MVs coming f rom cells cultured in 
hy poxic conditions, in which the number is more than doubled.  
 
We also analyzed the MVs coming from the blood of patients affected by a hormonal therapy resistant (HTR) breast 
cancer, by NanoSight (Figure 3). The result showed that they have a larger mean size compared to microvesicles coming 
from our cell lines (192 nm vs. 179-186 nm); their number is around 3x108 when 5 ml of serum are centrifuged.  
 
    
Figure 3: NanoSight diagram of microvesicles isolated from blood of a patient with hormonal therapy resistant breast cancer. 
Microv esicles isolated by ultracentrifugation show a larger size compared to the MVs coming f rom cells grown in normoxic or hypoxic 
conditions. Their number is almost the same when 5 mls of serum are ultracentrifuged. 
 
 
 
 
 
B 
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By electron microscopy, we were able to determine the quality of the microvesicles isolated by ultracentrifugation (Figure 
4). As by NanoSight, the presence of microvesicles isolated from 106 Caski cancer cells (left picture) and from the patients 
blood was demonstrated (right picture).  
 
                                      MVs Caski cells (HPV16)                                   Mvs Specimen 6 (HTR BC)  
                                                                                                                           
Figure 4: Electron microscopy of MVs coming from Caski cell line (HPV16 positive) and from the blood of a patient with HTR 
breast cancer. The presence of MVs coming f rom Caski cell line and from the blood of a patient affected by HTR breast cancer is checked 
by  electron microscopy anamysis. From the pictures we could notice that MVs coming from the blood show less size v ariability compared to 
the MVs coming f rom the cell line.  
Viral and mitochondr ial DNA sequences in microvesicles 
 
Once we analyzed the quality of our microvesicles, we proceeded with the molecular analyses. First of all we determined 
the DNA concentration in microvesicles treated or not treated with DNaseI, an enzyme able to digest ssDNA and dsDNA, 
prior DNA extraction. The results are shown in figure 5. All cell lines, even if with some differences, showed a drop in the 
DNA concentration after DNaseI treatment. This led to the conclusion that some free DNA can be stuck on the 
microvesicles membrane and not being internalized in the MVs. After this result, all experiments were conducted with MVs 
treated with DNaseI prior each nucleic acids extraction, injection or exposure on cells to be sure that the DNA eventually 
amplified or transferred, was inside the microvesicles and not outside and to devoid for DNA contamination (free DNA in 
the media). 
 
 
Figure 5: Presence of free DNA molecules on the MVs membrane. MVs isolated by ultracentrifugation from tumor cells (HeLa, Caski, 
Namalwa, MCF7, ZR751) or fibroblasts (MRC5, HMF), were treated or not treated with DNAseI before DNA extraction. The [DNA] of  MVs 
treated with DNaseI was lower compared to MVs not treated indicating the presence of free DNA molecules on the MVs membranes. 
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Since many evidences either from literature or from our results, showed an increase in the MVs number when cells 
undergo HR treatments, we wanted to evaluate if even the DNA concentration in those microvesicles was higher. The 
DNA inside MVs coming from cells undergoing HR treatments was extracted and quantified by Nanodrop; as reported in 
figure 6, the DNA concentration/?l resulted higher in microvesicles coming from cells that underwent 3 rounds of HR 
treatment compared to cells cultured in normoxia or that underwent 1 or 2 rounds of HR treatments. Even if both Caski 
and HeLa cells are HPV positive cancer cells, there’s a big difference in their MVs content; undergoing the same HR 
treatments, Caski cells showed a constant increment of the DNA concentration in the microvesicles, while HeLa cells 
show a raise in DNA concentration only after the third round of HR treatment. 
 
 
Figure 6: HR treatments increase the concentration of the DNA inside the MVs during time.  The DNA concentration of microv esicles 
isolated from Caski and HeLa cells cultured under HR treatments during 3 weeks was evaluated. After 3 weeks of treatments the DNA 
concentration was constantly increased in Caski of about 5 times. In HeLa cells the DNA concentration suddenly increased of 40 times after 
the third round of HR treatments.  
The presence of the viral and genomic DNA was demonstrated by qPCR. In figure 7 we report a bar graph indicating the 
copy number variation of GAPDH, Beta Actin and HPV DNA in Caski and HeLa cells cultured in normoxic conditions or 
after 3 rounds of HR treatments. As showed previously, the copy number increases after the HR treatments compared to 
the normoxic ones.   
 
 
Figure 7: Presence of viral and genomic DNA in MVs coming from HPV positive cell lines. A qPCR f or the human GAPDH, Beta Actin 
and HPV DNAs in MVs was perf ormed in order to calculate their copies number in normoxic or HR MVs. The amount of genomic and viral 
DNA increases in HR MVs mostly in the Caski cells compared to the HeLa. 
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Once we analyzed the presence and the copy number of viral and genomic DNA in the MVs, we compared the DNA copy 
number in HR MVs compared to the cells from which they come from (Figure 8). While the copy number of the genomic 
genes in the cells and MVs was almost the same in the HPV16 positive (Caski), HPV18 positive (HeLa) and the EBV 
positive (Namalwa) cells, the viral copy number changed more, maybe because of the different sites of viral DNA 
integration in the cells.  
 
 
Figure 8: High variation in the viral genes copy number between cells and their MVs, compared to the genomic ones. The genomic 
DNA copy  number calculation of v iral and genomic DNA sequences in cells versus their respective microvesicles was calculated after 
qPCR amplification. Housekeeping’s gene copy number is reported as a mean of the two cell lines 
Human fibroblasts (hCAFs) and cancer cells (Caski) were tested for the presence of mitochondrial DNA (mtDNA) by 
qPCR in MVs treated or not treated with DNaseI prior DNA extraction. Figure 9 shows how, after DNAseI treatment, the 
ratio between the mtDNA and the nuclear DNA (nDNA) increases, leading to the conclusion that the mtDNA was mostly 
present inside the MVs.  
 
 
Figure 9: Presence of mitochondrial (ND1) and nuclear (GAPDH) DNA in MVs. MVs isolated from human fibroblasts and cancer cells 
were treated or not treated with DNaseI prior DNA extraction. After treatment, the ratio between the mtDNA and the nDNA increases mostly 
in the cancer cell lines meaning that, in these cells, the mtDNA is enriched in MVs coming f rom cancer cells compared to the nDNA. 
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Other than a real time assay, the presence of the mitochondrial DNA in the MVs was also evaluated by PCR. All 
mitochondrial genes were screened in MVs coming from HR HeLa cells. After amplification we loaded the samples on a 
2% agarose gel, showed in figure 10. 
 
 
Figure 10: All mitochondrial genes are present in the HR MVs coming from HeLa cells. HR MVs coming from HeLa cells were 
isolated by ultracentrifugation and treated with DNaseI followed by DNA extraction. The DNA inside the MVs was amplif ied with 14 primer 
pairs, covering the complete mtDNA genome.  
 
Given this result, we wondered if other than a fragmented DNA, a complete circular mitochondrial DNA was present in the 
MVs. Therefore, we amplified the DNA coming from both the cells and the resulting MVs using three overlapping primers 
pairs, which permitted the amplification of the entire mtDNA. The primers used in this screen gave rise to amplicons of 
about 4, 5 and 9 Kbs. We were able to amplify the third region with a really lower efficiency compared to the other two 
regions in both the cells and the MVs, probably because the excessive length of the amplicon.  
In figure 11 we show an example of long PCR amplification on HeLa cells.  
 
 
Figure 11: Presence of possibly entire, circular mtDNA molecules in the MVs. A Long PCR assay on mtDNA in microvesicles coming 
from HeLa HR MVs and cells was performed. The primers cov ered the regions comprised between the D-loop and the ND1 (3968 bps), the 
ND1 and the COX3 (5513 bps) and the ATP6 and the D-loop (9289 bps).  
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The specificity of the viral DNAs and the mtDNA in the microvesicles was confirmed by sequencing. In Figure 12 we 
report an example of sequencing diagram of the LMP2 EBV amplicon deriving from MVs isolated from Namalwa cells. 
 
Figure 12: Sequencing of the LMP2 EBV gene. The v iral and mitochondrial products of amplif ication were loaded on an agarose gel, 
extracted and sequenced. The sequenced was then blasted with the ref erence sequence on PubMed.  
 
Viral and mitochondr ial DNA transfer by microvesicles in vitro 
 
Once we established that both the viral and the mitochondrial DNA sequences were present in the MVs, we performed in 
vitro experiments in order to evaluate if the DNA could be transferred to recipient cells. Viral negative recipient cells were 
exposed to fluorescent labeled MVs isolated from Caski, HeLa and Namalwa cells that underwent HR treatments. After 2 
hours of exposure we looked at the recipient cells by confocal microscopy and saw that, while the fibroblasts were already 
positive for the MVs staining, cancer cells were sti ll negative. After 12 hours also the epithelial cells became positive for 
the MVs staining. In figure 13 we show two pictures took by confocal microscopy of both fibroblasts and cancer cells 
positive to the MVs. In order to visualize the cellular compartment in which the MVs were up taken, we used MitoTracker 
(red) to trace the mitochondria, DAPI (blue) to visualize the nuclei and PKH67 cellular linker (green) for the MVs. In this 
way we were able to visualize the MVs co-localization with the mitochondrial compartment and the nucleus. By this 
analysis we were able to see that while the microvesicles up taken by fibroblasts were mainly localize in the mitochondrial 
compartment, the microvesicles in the cancer cells were localized both in the nucleus and the mitochondria. 
 
                                                 Fibroblasts                                                                 Cancer Cells 
    
Figure 13: Transfer of HeLa HR MVs to fibroblasts and cancer cells in vitro. Fibroblasts and cancer cells were exposed to HR HeLa 
MVs. Fibroblasts exposed to MVs showed a high up take after only 2 hours while cancer cells turned positiv e after 12 hours. MVs are 
mainly present in the cytoplasm of the f ibroblasts while are almost equally distributed between the cytoplasm and the nucleus in the cancer 
cells.  
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The viral and mitochondrial DNA transfer was evaluated by PCR and qPCR. In order to evaluate if there was any 
difference between the transfer of nucleic acids from hypoxic or normoxic MVs to recipient cells, we exposed recipient 
cells (105 cells) to MVs (108 particles) every 48 hours for a week. As reported in figure 14, the recipient cells exposed to 
MVs derived from HR cells, show a higher viral DNA copy number compared to those which received the normoxic MVs. 
We exposed two cancer cell lines (MCF7 and ZR751) and one human fibroblast cell line (BR11) to the MVs coming from 
normoxic and hypoxic Namalwa cells (EBV positive) and evaluated the viral copy number in the recipient cells after 24 
hours post exposure; we saw that 1) the viral DNA copy number in the fibroblasts wa s higher compared to the cancer 
cells and 2) the viral DNA copy number in cells exposed to normoxic MVs was almost zero compared to the viral copy 
number in cells exposed to HR MVs.  
 
Figure 14: Viral DNA transfer to recipient cells through MVs. Normoxic and HR EBV positiv e microvesicles were isolated by 
ultracentrif ugation, treated with DNaseI, and bumped on both viral negative cancer cells and f ibroblasts every 48 hours f or a week. After 7 
days, the cells were washed in 1X PBS and the DNA was extracted. Cells exposed to HR microv esicles show a higher number of viral copy 
number compared to those exposed to normoxic MVs. Also, the viral copy number in fibroblasts is higher than in the cancer cells, in which 
is almost the same between three different cell lines. 
The transfer of the mitochondrial DNA was evaluated exposing human mammary cancer cells (BT474) to MVs coming 
from murine cancer associated fibroblasts (mCAFs). By using primers that targeted all the mitochondrial genes, we were 
able to amplify the whole mitochondrial genome, meaning that the mtDNA was transferred. As reported in figure 15, we 
weren’t able to amplify the murine genomic genes (COX4 and ?2M).  
 
 
 
Figure 15: mtDNA transfer to recipient cells through MVs. MVs f rom murine CAFs were treated with DNaseI and dumped on BT474 
cells. The transf er of the murine mtDNA to human recipient cells was ev aluated by amplifying all the murine mitochondrial genes by qPCR.  
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Viral nucleic acids transfer through microvesicles in vivo 
 
The positive results in vitro prompted us to analyze the transfer of viral DNA sequences in vivo. We injected 106 MVs from 
Caski, HeLa and Namalwa cells 4 times/month in the arterial circulation of mice bearing luminal breast cancer xenografts 
(MCF7 or ZR751 cells). Following a period of 5 months of MVs education mice were sacrificed. By colorimetric in situ 
hybridization (CISH) and PCR we were able to identify HPV DNA (E6 and E7) and EBV RNA (EBER1) sequences in 
tissues, including cancer cells and fibroblasts, both in primary tumor and in the metastatic microenvironment. In figure 16 
the positivity to the HPV, EBV sequences is shown.  
 
 
Figure 16: Transfer of viral nucleic acids through microvesicles, in vivo. MVs isolated from HPV and EBV positive cell lines. After 
NanoSight analysis, 106 MVs were treated with DNaseI and intravenously injected in breast cancer xenografts. The HPV DNA and the EBV 
RNA from viral positive MVs in xenografts was identified by CISH in the tumor and in some murine f ibroblasts surrounding the tumor. 
Analysis of viral and mitochondrial DNA in ex vivo microvesicles  
 
To translate our discovery to patient-derived specimens, we isolated MVs from two distinct breast cancer cohorts and 
analyzed the presence of HPV DNA sequences by qPCR. The results on the MVs isolated by newly diagnosed breast 
cancer patients, showed the presence of HPV DNA in the 11% of the total MVs (8/68), with a 6% of positivity for the 
HPV18 (4/68), a 4% to the HPV16 (3/68) and a 1% of positivity to the HPV31 (1/68). When the analysis was conducted on 
MVs coming from patients affected by hormonal therapy resistant breast cancer, the results showed a total positivity of the 
14% (9/65) with a 6% positive for the HPV16 (4/65), a 5% positive for the HPV18 (3/65), and a 3% of co-infection of 
HPV16 and HPV18 (2/65). These data are summarized in figure 17. 
 
 
Figure 17: Presence of HPV DNA sequences in MVs coming from the blood of patients affected by breast cancer. MVs coming from 
the circulation of newly diagnosed breast cancer patients and affected by HTR breast cancer were treated with DNaseI. The DNA was 
extracted and screened for the presence of the E6 region of the HPV by PCR and qPCR.   
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The HPV16/18 DNA copy number was evaluated in the HTR cohort only and is shown in figure 18. 
 
 
Figure 18: Copy number evaluation of the HPV18 and HPV16 DNA in the circulating MVs of patients affected by HTR breast 
cancer. The copy number of the v iral DNA amplified in the MVs of patients affected by HTR breast cancer was evaluated after amplif ication 
by  qPCR.  
Other than the HPV DNA analysis, the presence of GAPDH and ND1 was evaluated by qPCR in the HTR cohort. GAPDH 
DNA sequences where found in the 36% of the microvesicles (26/72) while the mitochondrial ND1 gene was amplified in 
the 72% of the microvesicles (52/72). 
 
Analysis of the chemical-physical status of nucleic acids in MVs  
 
The presence of the viral RNA in MVs coming from HeLa, Caski and Namalwa cells was analyzed by PCR. To analyze 
the presence of the RNA, we used primers able to amplify both the DNA and the RNA at the same time since they are 
designed to span an intron and they give rise to amplicons of different lengths. Although we were able to identify the viral 
RNA in the MVs, we also noticed that, even after DNaseI treatment of the RNA prior retro-transcription, we were 
amplifying viral DNA. The presence of both the viral DNA and the cDNA in the MVs coming from HR HeLa but not in the 
cells is shown in figure 19. 
 
Figure 19: Presence of DNaseI resistant viral DNA in the RNA fraction of HR MVs. The RNA coming f rom HR viral positive MVs and 
cells was extracted and treated with DNaseI prior retro-transcription. By using primers able to amplify both the RNA and the possible 
contaminating DNA we were able to identify some viral DNA resistant to the nuclease’s treatment. 
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Since this result was mainly obtained in HR MVs than in normoxic MVs, we hypothesized that the nuclease’s resistant 
DNA could be incorporated in a more complex structure, like an R-loop, known to be more synthesized in hypoxic 
conditions. Therefore, we analyzed the physical and chemical status of the DNA in the RNA fraction by using different 
nucleases. In figure 20 the viral DNA copy number amplified in the RNA treated with different nucleases is shown. The 
nDNA sequences in the RNA fraction were mostly characterized by dsDNA since after DNaseI treatment they showed a 
drastic drop in their copy number. At the contrary, the viral DNA sequences persisted after DNaseI treatment and were 
mostly eliminated after RNaseH treatment (which digests the RNA in the R-loop structure) and ExonucleaseS1 digestion 
(which digests the ssDNA), which supports the hypothesis that viral DNA could be protected by a more complex structure. 
  
 
Figure 20: Presence of viral DNA complexes in R-loop structures in HR HeLa MVs. RNA was extracted from HR viral positive MVs 
and not treated with DNaseI (blue), treated with DNaseI (red), treated with DNaseI, RNaseA and H (green) and treated with DNaseI 
RNaseA and H and ExonucleaseS1 (pink). The viral DNA copy number shows a drop in after treatment with both the RNases and the 
Exonuclese S1. The nDNA, instead, shows a drop mainly after DNaseI treatment.  
Since microvesicles coming from cells grown in normoxia or hypoxia showed different concentration of DNA (Figure 6), 
we wanted to evaluate if even the chemical-physical status of the DNA in the MVs was different. To do that, we performed 
nucleases treatments on normoxic or hypoxic HeLa MVs and did the qPCR on the viral DNA. In figure 21 the viral copy 
number is shown. As reported in the figure, the viral copy number in the hypoxic MVs showed a drop after treatment with 
RNAseA/H and ExonucleaseI. In the normoxic MVs, instead, the copy number after these treatments remained almost the 
same. This result means that the viral DNA in the hypoxic MVs is combined with some RNAs in a more complex structure 
while the viral DNA in the normoxic MVs seems to be a dsDNA, since after DNaseI treatment the drop is more evident.  
 
 
Figure 21: HR MVs have show a prevalence of viral DNA complexes in R-loops compared to normoxic MVs. The RNA coming from 
normoxic or HR MVs was treated as reported in Fig. 20. The viral DNA showed a drop in the HR MVs mainly after treatment with nucleases 
which digest the RNA in the R-loops. In normoxic conditions, instead, the drop is visualized mainly before treatment with the Exo S1 
nuclease. 
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The same experiments were conducted on EBV positive MVs and the qPCR products were run on an agarose gel in order 
to confirm the obtained data. In picture 22 the agarose gel for the EBV, GAPDH and 12S genes amplified after nucleases 
treatment is reported. The GAPDH gene, found in a dsDNA form since is not eliminated after RNaseH and ExoS1 
treatment. The viral and mitochondrial sequences (the 12S gene is known to be characterized by a R-loop structure) are 
affected by this last treatment. Differences between the GAPDH bands are not evident prior and post DNaseI due to the 
high number of cycles that we had to perform in order to amplify the viral DNA, which means that its amplification reached 
the plateau. 
 
Figure 22: Presence of viral but not nuclear DNA in a R-loop structure in EBV positive HR MVs. DNA f rom Namalwa MVs was 
amplified 1) without DNaseI treatment, 2) after DNaseI treatment, 3) after DNAseI and RNaseH treatment and 4) after DNAseI, RNaseH 
and ExoS1 treatment 
In order to confirm the results on the R-loop status of the viral DNA we performed a DNA:RNA immunoprecipitation 
(DRIP), in which an antibody specific for the DNA:RNA hybrids is used to separate them from the others RNA 
components. The control of the experiment was characterized by the immunoprecipitation of RNA previously treated with 
RNAseH, so that in this sample, no DNA amplification should have been determined in the bound fraction.  
In figure 23 we report the schematic mechanism of the DRIP assay that takes advantage of an antibody that specifically 
binds the R-loops called S9.6 Ab.      
 
 
Figure 23: Schematic mechanism of the DRIP assay. Without RNaseH treatment, the Ab can bind the R-loops (bound f raction) 
discriminating from the other RNA components (unbound fraction). When the RNA is treated with the RNaseH before the DRIP, the RNA 
molecule in the R-loop is digested; this impedes the Ab to bind the R-loops leading to the presence of  the DNA of the DNA:RNA hy brid in 
the unbound fraction. 
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In figure 24 we show an agarose gel coming from a DRIP experiment conducted on HR HeLa MVs. Thanks to primers 
able to amplify both the DNA and the RNA in the same reaction, we were able to identify the viral sequences in the bound 
and unbound fractions, demonstrating the presence of the R-loops. 
  
 
Figure 24: Presence of viral R-loop sequences in HR HeLa MVs by DRIP. When the RNA wasn’t treated with the RNAseH, the antibody 
bound the R-loops, and we were able to amplify both the viral DNA and the RNA (4), while the unbound fraction contained the v iral mRNAs 
only  (2); When the RNA was treated with the RNaseH before the DRIP assay, the antibody could no longer bind the R-loops since the RNA 
molecule was digested. In the unbound f raction we were able to amplify both the v iral DNA and RNA (3) while in the bound f raction there 
was no amplification (5). 
 
 
By qPCR we were able to calculate the viral RNA copy number of the viral and the difference between the 4 different 
fractions. As reported in figure 25, in the not RNaseH treated bound fraction, we found an increase of the viral cDNA of 
almost 80 times compared to the other three fractions.  
 
 
Figure 25: Prevalence of viral RNA in a R-loop form than a mRNA form in HR HeLa MVs. DRIP assay on HR HPV positive MVs. The 
RNA treated or not treated with RNaseH was dripped and amplified by qPCR for the HPV cDNA. An almost 80 f old increase was 
determined when the RNA was amplified in the f raction containing the R-loops structures compared to the other fractions. 
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The presence of complex structures in the microvesicles was finally confirmed by Atomic Force Microscopy (AFM). The 
nucleic acids coming from HeLa MVs and treated with nucleases were analyzed. In figure 26 we report a picture took by 
AFM in which is possible to see the difference between the nucleic acids not treated with the nucleases (Panel A) and the 
ones treated with DNaseI, RNaseH and ExonucleaseS1 (Panel B).  
 
     
       
Figure 26: Presence of complex structure in the DNA coming from HR HeLa MVs by Atomic Force Microscopy. (A)The DNA not 
treated with the nucleases is mostly composed by dsDNA, characterized by less thick fragments (purple structures) in the picture. (B) The 
DNA treated with the DNaseI, RNaseH and ExoS1 is mostly characterized by complex structures which are resistant to the enzymes action 
and show a higher thickness compared to the linear dsDNA. 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 46 
Discussion and conclusion 
 
By using cell l ines positive for HPV18/16 (Hela/Caski) and EBV (Namalwa) DNA, we were able to isolate 
microvesicles (MVs) positive for viral DNAs. The quality of the microvesicles was tested by electron 
microscopy and NanoSight analysis. These MVs were used for in vitro and in vivo experimental studies 
since they have been either exposed on recipient viral-nucleic acids-negative cells or intravenously 
injected in breast cancer xenografts. Since the MVs release is different from cells that are cultured in 
normoxia versus cells grown in hypoxia, we started analyzing if even in our experimental conditions the 
number of hypoxic MVs was higher than the normoxic ones. After having cultured cells in normoxia or 
cells that underwent 3 rounds of normoxia and hypoxia treatments, we isolated the MVs and notices that 
the number of hypoxic MVs was doubled compared to the normoxic ones. We then analyzed the same 
number of MVs for their DNA concentration and saw a higher concentration in hypoxic/re-oxigenated 
(HR) MFVs, by Nanodrop. The data was confirmed by qPCR, in which we saw a higher copy number for 
the nuclear genes (GAPDH, Actin) and the viral oncogenes (HPV16, HPV18 and EBV). MVs Murine 
cancer associated fibroblasts (mCAFs) were used to study the mitochondrial DNA (mtDNA) transfer: MVs 
isolated from mCAFs were exposed on human mammary cancer cell lines in vitro in order to evaluate the 
transfer of the mtDNA from one cell to another. After the exposure of the recipient cells to the MVs, we 
were able to analyze the presence of the viral and mtDNA by PCR and qPCR in the recipient cells in 
more than one cell line model, but not all. The reason is probably due to the cellular variability and thus, 
suggests that some cells could be more prone to up take MVs than others. Other than that we visualized, 
by confocal microscopy, that the time of uptake was different between cancer cells and fibroblasts: the 
first ones internalized the MVs after about 12 hours while the fibroblasts were positive after only 2 hours 
post exposure. After the injection of the viral MVs in breast cancer xenografts, we analyzed the presence 
of the viral DNA (HPV) and RNA (EBV) by colorimetric in situ hybridization (CISH) and were able to 
identify the nucleic acids in the cancer cells and the surrounding stromal cells. This data was confirmed 
by creating a Caski xenograft (HPV16 positive cancer cell line): the viral DNA was identified in the stromal 
compartment also, meaning that the cancer cells produced viral DNA positive MVs that were then up 
taken by the surrounding stromal cells.  
Mitochondrial DNA in the MVs coming from cells that underwent HR treatments was amplified by qPCR 
and PCR assay. Interestingly, the copy number results showed that mtDNA is enriched in the MVs 
compared to other nuclear genes (GAPDH) leading to the hypothesis that these microvesicles can 
actually transfer their content to recipient cells and lead to the development of a heterogeneous 
environment.  
By using primers able to amplify both the DNA and the RNA at the same time (the primers are designed 
so that they can span the intron between two exons giving rise to two amplicons of different length), we 
noticed the presence of viral but not nuclear genes in the RNA fraction of viral positive HR MVs (HeLa 
and Namalwa MVs) even after DNA digestion with DNases treatment (the DNases used in these 
experiments targeted both the ssDNA and the dsDNA). We then hypothesized that the DNAs that we 
were able to amplify after nucleases treatment could be protected from the enzyme action and thus, be 
part of a more complex structure, l ike an R-loop. In fact, the presence of the resistant DNA was mostly 
found in HR MVs compared to the normoxic ones and is known that R-loops structures are synthesized 
more under hypoxic conditions. We thus decided to analyze the status of the viral ad mtDNA in the MVs. 
After the isolation of the RNA from the viral positive MVs we treated it with different nucleases in order to 
get rid of the contaminating ss- and dsDNAs; we then treated it with RNases specific for the ss- and ds-
RNAs and with a specific RNAse which digests the RNA molecule in the DNA:RNA hybrid. After all these 
steps we performed PCRs and still  we were able to amplify the viral sequences. Only after a last step in 
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which we repeated the treatment with a ssDNA specific DNase, we were no longer able to visualize the 
viral DNA, leading to the conclusion that the viral DNA was effectively part of the DNA:RNA hybrid 
structure. Since R-Loops are known to be really stable structures, we hypothesized that the viral DNA 
could be incorporated in these complexes and be more protected from cellular degradation once the MVs 
get in the recipient cells. To verify these results, we performed a DNA/RNA immunoprecipitation (DRIP) 
using a specific antibody, which recognizes the R-loop structure, in the RNA coming from HeLa HR MVs 
and looked for the presence of both genomic and viral DNA in the bound and unbound fractions. Thanks 
to a copy number analysis, we were able to identify a fold increase of 80 times of the viral DNA sequence 
in the bound (R-loop enriched) fraction compare to the unbound fraction.  
After having conducted all these experiments in vitro, we decided to analyze the presence of viral and 
mitochondrial DNA in circulating MVs coming from newly diagnosed breast cancer patients, collected by 
the Sant’ Orsola-Malpighi Hospital, located in Bologna, Italy, and patients affected by hormonal therapy 
resistant breast cancer, collected by the Memorial Sloan Kettering Cancer Center (MSKCC), located in 
New York, USA. Analyzing the Italian cohort, we were able to identify HPV DNA sequences in the 11% 
(8/68) of the samples by PCR; the 4% of the samples tested positive to the HPV16 (3/68), the 6% to the 
HPV18 DNA (4/68) and the 1% to the HPV31. In the American cohort we were able to screen the viral, 
nuclear and mtDNA and calculate their copy number. The data showed a total positivity of the 14% to the 
viral DNAs (9/65); HPV16 was found in the 6% (4/65) of the samples, the HPV18 in the 5% (3/65) and the 
3% of the samples (2/65) showed the presence of a HPV16/18 co-infection. The presence of the 
mitochondrial DNA was evaluated and found in the 72% of the specimens compared to a 37% of positivity 
to the GAPDH gene. This results lead to hypothesize that nuclear, viral and mitochondrial DNAs are 
probably released in different ways and amounts depending on the cells releasing them and the 
pathological conditions of the patients. 
Finally, the complex nucleic acids structures obtained after nucleases treatments were visualized by 
atomic force microscopy. In particular, we compared the DNA not treated with nucleases or treated with 
DNaseI, RNaseH and ExonucleaseS1, coming from HPV and EBV DNA positive HR MVs. By AFM we 
could see how the not treated fraction was mainly characterized by dsDNAs while the treated one mainly 
showed the presence of structures with a higher color density, which correlates with a higher structure 
complexity.   
Thanks to these experiments, we were able to determine a possible mechanism of viral nucleic acids 
transfer from a primary site of infection to different not permissive tissues, through microvesicles together 
with their chemical-physical status. We were able to verify a possible mechanism of mitochondrial DNA 
transfer from one cell to another, opening the possibility of a different acquisition of foreign material 
through microvesicles, in a neoplastic environment. We identified viral DNA sequences in circulating MVs 
of breast cancer patients either newly diagnosed or affected by a hormonal therapy resistant disease and 
we also demonstrated a high presence of mtDNA in the microvesicles in the American cohort.  
Taken together, these data demonstrate how microvesicles can play a role in the tumor heterogeneity 
development. Further studies will be conducted in order to evaluate a possible correlation between the 
presence of the viral and mtDNA in MVs and development of an aggressive tumor phenotype in breast 
cancer patients, analyzing the mtDNA also in the MVs of newly diagnosed breast cancer patients and 
comparing it to the MVs of patients with an HTR disease; also further investigation will be conducted to 
understand if the viral and mitochondrial nucleic acids transferred by microvesicles can be responsible for 
metastatic progression and resistance to therapies in luminal breast cancer models. 
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